AU714607B2 – Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
– Google Patents
AU714607B2 – Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
– Google Patents
Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
Download PDF
Info
Publication number
AU714607B2
AU714607B2
AU47599/96A
AU4759996A
AU714607B2
AU 714607 B2
AU714607 B2
AU 714607B2
AU 47599/96 A
AU47599/96 A
AU 47599/96A
AU 4759996 A
AU4759996 A
AU 4759996A
AU 714607 B2
AU714607 B2
AU 714607B2
Authority
AU
Australia
Prior art keywords
group
amino
oxoethyl
lower alkyl
hydrogen
Prior art date
1995-01-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47599/96A
Other versions
AU4759996A
(en
AU714607C
(en
Inventor
Anthony Cerami
John J Egan
San-Bao Hwang
Peter C. Ulrich
Sara Vasan
Dilip R Wagle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Synvista Therapeutics Inc
Original Assignee
Alteon Inc
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1995-01-18
Filing date
1996-01-18
Publication date
2000-01-06
1995-01-18
Priority claimed from US08/375,155
external-priority
patent/US5656261A/en
1996-01-18
Application filed by Alteon Inc, Picower Institute for Medical Research
filed
Critical
Alteon Inc
1996-01-18
Priority claimed from US08/588,249
external-priority
patent/US5853703A/en
1996-08-07
Publication of AU4759996A
publication
Critical
patent/AU4759996A/en
2000-01-06
Application granted
granted
Critical
2000-01-06
Publication of AU714607B2
publication
Critical
patent/AU714607B2/en
2000-12-14
Publication of AU714607C
publication
Critical
patent/AU714607C/en
2016-01-18
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
150000001875
compounds
Chemical class
0.000
title
claims
description
134
108010005094
Advanced Glycation End Products
Proteins
0.000
title
claims
description
66
230000015572
biosynthetic process
Effects
0.000
title
claims
description
47
125000000217
alkyl group
Chemical group
0.000
claims
description
173
125000003118
aryl group
Chemical group
0.000
claims
description
115
102000004169
proteins and genes
Human genes
0.000
claims
description
84
108090000623
proteins and genes
Proteins
0.000
claims
description
84
229910052739
hydrogen
Inorganic materials
0.000
claims
description
83
239000001257
hydrogen
Substances
0.000
claims
description
83
CPELXLSAUQHCOX-UHFFFAOYSA-M
Bromide
Chemical compound
[Br-]
CPELXLSAUQHCOX-UHFFFAOYSA-M
0.000
claims
description
75
238000000034
method
Methods
0.000
claims
description
68
-1
hydroxy, amino
Chemical group
0.000
claims
description
56
150000003839
salts
Chemical class
0.000
claims
description
55
239000000203
mixture
Substances
0.000
claims
description
46
125000002924
primary amino group
Chemical group
[H]N([H])*
0.000
claims
description
46
206010012601
diabetes mellitus
Diseases
0.000
claims
description
45
UFHFLCQGNIYNRP-UHFFFAOYSA-N
Hydrogen
Chemical compound
[H][H]
UFHFLCQGNIYNRP-UHFFFAOYSA-N
0.000
claims
description
43
125000005843
halogen group
Chemical group
0.000
claims
description
36
150000002431
hydrogen
Chemical class
0.000
claims
description
35
125000005530
alkylenedioxy group
Chemical group
0.000
claims
description
33
125000003545
alkoxy group
Chemical group
0.000
claims
description
32
125000003277
amino group
Chemical group
0.000
claims
description
26
238000001727
in vivo
Methods
0.000
claims
description
21
125000002887
hydroxy group
Chemical group
[H]O*
0.000
claims
description
20
125000004423
acyloxy group
Chemical group
0.000
claims
description
19
125000001475
halogen functional group
Chemical group
0.000
claims
description
19
230000006378
damage
Effects
0.000
claims
description
18
125000003342
alkenyl group
Chemical group
0.000
claims
description
16
125000004453
alkoxycarbonyl group
Chemical group
0.000
claims
description
15
125000000449
nitro group
Chemical group
[O-][N+](*)=O
0.000
claims
description
15
125000000304
alkynyl group
Chemical group
0.000
claims
description
14
125000004356
hydroxy functional group
Chemical group
O*
0.000
claims
description
14
125000001997
phenyl group
Chemical group
[H]C1=C([H])C([H])=C(*)C([H])=C1[H]
0.000
claims
description
14
230000002401
inhibitory effect
Effects
0.000
claims
description
13
239000000463
material
Substances
0.000
claims
description
13
210000003743
erythrocyte
Anatomy
0.000
claims
description
12
125000000979
2-amino-2-oxoethyl group
Chemical group
[H]C([*])([H])C(=O)N([H])[H]
0.000
claims
description
11
150000001450
anions
Chemical class
0.000
claims
description
11
210000003734
kidney
Anatomy
0.000
claims
description
11
210000004369
blood
Anatomy
0.000
claims
description
10
239000008280
blood
Substances
0.000
claims
description
10
201000008482
osteoarthritis
Diseases
0.000
claims
description
10
235000000346
sugar
Nutrition
0.000
claims
description
10
208000002177
Cataract
Diseases
0.000
claims
description
9
102000014824
Crystallins
Human genes
0.000
claims
description
9
108010064003
Crystallins
Proteins
0.000
claims
description
9
206010020772
Hypertension
Diseases
0.000
claims
description
9
208000017442
Retinal disease
Diseases
0.000
claims
description
9
206010038923
Retinopathy
Diseases
0.000
claims
description
9
230000002411
adverse
Effects
0.000
claims
description
9
208000033808
peripheral neuropathy
Diseases
0.000
claims
description
9
CEAFABGKSOIJLH-UHFFFAOYSA-M
1-phenyl-2-(1,3-thiazol-3-ium-3-yl)ethanone;bromide
Chemical compound
[Br-].C=1C=CC=CC=1C(=O)C[N+]=1C=CSC=1
CEAFABGKSOIJLH-UHFFFAOYSA-M
0.000
claims
description
8
208000007342
Diabetic Nephropathies
Diseases
0.000
claims
description
8
238000002845
discoloration
Methods
0.000
claims
description
8
238000000338
in vitro
Methods
0.000
claims
description
8
210000000214
mouth
Anatomy
0.000
claims
description
7
OBUCDWPHAVUUMH-UHFFFAOYSA-M
1-(1,3-thiazol-3-ium-3-yl)propan-2-one;chloride
Chemical compound
[Cl-].CC(=O)C[N+]=1C=CSC=1
OBUCDWPHAVUUMH-UHFFFAOYSA-M
0.000
claims
description
6
IWSVLBKHBJGMAA-UHFFFAOYSA-M
2-(3-benzyl-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;chloride
Chemical compound
[Cl-].CC1=C(CCO)SC=[N+]1CC1=CC=CC=C1
IWSVLBKHBJGMAA-UHFFFAOYSA-M
0.000
claims
description
6
NWYBJPXXICNVLX-UHFFFAOYSA-M
2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;bromide
Chemical compound
[Br-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1
NWYBJPXXICNVLX-UHFFFAOYSA-M
0.000
claims
description
6
FJNLZJRANZQMNW-UHFFFAOYSA-M
2-(4-methyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;bromide
Chemical compound
[Br-].CC1=CSC=[N+]1CC(=O)C1=CC=CC=C1
FJNLZJRANZQMNW-UHFFFAOYSA-M
0.000
claims
description
6
201000001320
Atherosclerosis
Diseases
0.000
claims
description
6
208000033679
diabetic kidney disease
Diseases
0.000
claims
description
6
230000002255
enzymatic effect
Effects
0.000
claims
description
6
239000008194
pharmaceutical composition
Substances
0.000
claims
description
6
YMDGVTUTKWNMHD-UHFFFAOYSA-M
2-(3-amino-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=C(CCO)SC=[N+]1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
YMDGVTUTKWNMHD-UHFFFAOYSA-M
0.000
claims
description
5
ASBQERCSEDFCII-UHFFFAOYSA-M
2-(5-ethenyl-4-methyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;bromide
Chemical compound
[Br-].CC1=C(C=C)SC=[N+]1CC(=O)C1=CC=CC=C1
ASBQERCSEDFCII-UHFFFAOYSA-M
0.000
claims
description
5
DQNULYVAORUBAJ-UHFFFAOYSA-N
2-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]acetamide;bromide
Chemical compound
[Br-].CC1=C(CCO)SC=[N+]1CC(N)=O
DQNULYVAORUBAJ-UHFFFAOYSA-N
0.000
claims
description
5
230000003247
decreasing effect
Effects
0.000
claims
description
5
125000004435
hydrogen atom
Chemical group
[H]*
0.000
claims
description
5
238000004519
manufacturing process
Methods
0.000
claims
description
5
125000002496
methyl group
Chemical group
[H]C([H])([H])*
0.000
claims
description
5
210000005166
vasculature
Anatomy
0.000
claims
description
5
YLMFMJQOTNHWFW-UHFFFAOYSA-N
1,3-thiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
NC=1SC=C[N+]=1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
YLMFMJQOTNHWFW-UHFFFAOYSA-N
0.000
claims
description
4
ORECNKBJIMKZNX-UHFFFAOYSA-N
1,3-thiazol-3-ium;chloride
Chemical compound
Cl.C1=CSC=N1
ORECNKBJIMKZNX-UHFFFAOYSA-N
0.000
claims
description
4
XJQGECHIHFUWEN-UHFFFAOYSA-N
2-(1,3-benzothiazol-3-ium-3-yl)acetamide;bromide
Chemical compound
[Br-].C1=CC=C2[N+](CC(=O)N)=CSC2=C1
XJQGECHIHFUWEN-UHFFFAOYSA-N
0.000
claims
description
4
208000000575
Arteriosclerosis Obliterans
Diseases
0.000
claims
description
4
206010018364
Glomerulonephritis
Diseases
0.000
claims
description
4
208000030831
Peripheral arterial occlusive disease
Diseases
0.000
claims
description
4
208000018262
Peripheral vascular disease
Diseases
0.000
claims
description
4
208000006011
Stroke
Diseases
0.000
claims
description
4
201000010099
disease
Diseases
0.000
claims
description
4
208000037265
diseases, disorders, signs and symptoms
Diseases
0.000
claims
description
4
206010061989
glomerulosclerosis
Diseases
0.000
claims
description
4
230000003902
lesion
Effects
0.000
claims
description
4
230000011164
ossification
Effects
0.000
claims
description
4
230000037303
wrinkles
Effects
0.000
claims
description
4
125000004429
atom
Chemical group
0.000
claims
description
3
125000005594
diketone group
Chemical group
0.000
claims
description
3
230000000269
nucleophilic effect
Effects
0.000
claims
description
3
238000011160
research
Methods
0.000
claims
description
2
229920002554
vinyl polymer
Polymers
0.000
claims
2
238000013022
venting
Methods
0.000
claims
1
235000018102
proteins
Nutrition
0.000
description
77
238000006243
chemical reaction
Methods
0.000
description
47
239000003795
chemical substances by application
Substances
0.000
description
47
238000006206
glycosylation reaction
Methods
0.000
description
34
230000013595
glycosylation
Effects
0.000
description
32
239000008055
phosphate buffer solution
Substances
0.000
description
32
229940098773
bovine serum albumin
Drugs
0.000
description
31
239000000047
product
Substances
0.000
description
31
239000000243
solution
Substances
0.000
description
31
108091003079
Bovine Serum Albumin
Proteins
0.000
description
30
102000008186
Collagen
Human genes
0.000
description
30
108010035532
Collagen
Proteins
0.000
description
30
229920001436
collagen
Polymers
0.000
description
30
238000004132
cross linking
Methods
0.000
description
30
238000012360
testing method
Methods
0.000
description
30
WQZGKKKJIJFFOK-GASJEMHNSA-N
Glucose
Natural products
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-GASJEMHNSA-N
0.000
description
29
239000008103
glucose
Substances
0.000
description
27
DDGHBOLOCQWPKE-UHFFFAOYSA-N
1,3-thiazole;hydrobromide
Chemical compound
[Br-].C1=CSC=[NH+]1
DDGHBOLOCQWPKE-UHFFFAOYSA-N
0.000
description
24
LXFQSRIDYRFTJW-UHFFFAOYSA-M
2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
LXFQSRIDYRFTJW-UHFFFAOYSA-M
0.000
description
23
238000003556
assay
Methods
0.000
description
23
241001465754
Metazoa
Species
0.000
description
20
230000005764
inhibitory process
Effects
0.000
description
20
239000000872
buffer
Substances
0.000
description
19
238000011534
incubation
Methods
0.000
description
19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound
CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
18
230000002441
reversible effect
Effects
0.000
description
17
230000032683
aging
Effects
0.000
description
16
XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances
O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
15
229920000136
polysorbate
Polymers
0.000
description
14
GHXZTYHSJHQHIJ-UHFFFAOYSA-N
Chlorhexidine
Chemical compound
C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N
0.000
description
13
229960003260
chlorhexidine
Drugs
0.000
description
13
230000036252
glycation
Effects
0.000
description
13
230000000694
effects
Effects
0.000
description
12
241000700159
Rattus
Species
0.000
description
11
HAMNKKUPIHEESI-UHFFFAOYSA-N
aminoguanidine
Chemical compound
NNC(N)=N
HAMNKKUPIHEESI-UHFFFAOYSA-N
0.000
description
11
239000003153
chemical reaction reagent
Substances
0.000
description
11
238000003776
cleavage reaction
Methods
0.000
description
11
238000002474
experimental method
Methods
0.000
description
11
235000013305
food
Nutrition
0.000
description
11
230000007017
scission
Effects
0.000
description
11
239000007795
chemical reaction product
Substances
0.000
description
10
238000002360
preparation method
Methods
0.000
description
10
ULOCHOLAPFZTGB-UHFFFAOYSA-N
1,3-benzothiazol-3-ium;bromide
Chemical compound
[Br-].C1=CC=C2SC=[NH+]C2=C1
ULOCHOLAPFZTGB-UHFFFAOYSA-N
0.000
description
9
125000002915
carbonyl group
Chemical group
[*:2]C([*:1])=O
0.000
description
9
102000035122
glycosylated proteins
Human genes
0.000
description
9
108091005608
glycosylated proteins
Proteins
0.000
description
9
230000007246
mechanism
Effects
0.000
description
9
108090000765
processed proteins & peptides
Proteins
0.000
description
9
210000002435
tendon
Anatomy
0.000
description
9
IJGRMHOSHXDMSA-UHFFFAOYSA-N
Atomic nitrogen
Chemical compound
N#N
IJGRMHOSHXDMSA-UHFFFAOYSA-N
0.000
description
8
108010001336
Horseradish Peroxidase
Proteins
0.000
description
8
KDXKERNSBIXSRK-UHFFFAOYSA-N
Lysine
Natural products
NCCCCC(N)C(O)=O
KDXKERNSBIXSRK-UHFFFAOYSA-N
0.000
description
8
239000000499
gel
Substances
0.000
description
8
239000003112
inhibitor
Substances
0.000
description
8
239000000758
substrate
Substances
0.000
description
8
238000002965
ELISA
Methods
0.000
description
7
210000004408
hybridoma
Anatomy
0.000
description
7
230000003053
immunization
Effects
0.000
description
7
238000002649
immunization
Methods
0.000
description
7
239000000523
sample
Substances
0.000
description
7
239000000126
substance
Substances
0.000
description
7
YMWUJEATGCHHMB-UHFFFAOYSA-N
Dichloromethane
Chemical compound
ClCCl
YMWUJEATGCHHMB-UHFFFAOYSA-N
0.000
description
6
DNIAPMSPPWPWGF-UHFFFAOYSA-N
Propylene glycol
Chemical compound
CC(O)CO
DNIAPMSPPWPWGF-UHFFFAOYSA-N
0.000
description
6
230000008901
benefit
Effects
0.000
description
6
125000004432
carbon atom
Chemical group
C*
0.000
description
6
238000010790
dilution
Methods
0.000
description
6
239000012895
dilution
Substances
0.000
description
6
239000007788
liquid
Substances
0.000
description
6
230000001225
therapeutic effect
Effects
0.000
description
6
238000002560
therapeutic procedure
Methods
0.000
description
6
238000005406
washing
Methods
0.000
description
6
241000283707
Capra
Species
0.000
description
5
102000014914
Carrier Proteins
Human genes
0.000
description
5
108010078791
Carrier Proteins
Proteins
0.000
description
5
NBSCHQHZLSJFNQ-GASJEMHNSA-N
D-Glucose 6-phosphate
Chemical compound
OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O
NBSCHQHZLSJFNQ-GASJEMHNSA-N
0.000
description
5
VFRROHXSMXFLSN-UHFFFAOYSA-N
Glc6P
Natural products
OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O
VFRROHXSMXFLSN-UHFFFAOYSA-N
0.000
description
5
AFVFQIVMOAPDHO-UHFFFAOYSA-N
Methanesulfonic acid
Chemical compound
CS(O)(=O)=O
AFVFQIVMOAPDHO-UHFFFAOYSA-N
0.000
description
5
241000283973
Oryctolagus cuniculus
Species
0.000
description
5
230000002882
anti-plaque
Effects
0.000
description
5
ATDGTVJJHBUTRL-UHFFFAOYSA-N
cyanogen bromide
Chemical compound
BrC#N
ATDGTVJJHBUTRL-UHFFFAOYSA-N
0.000
description
5
238000001514
detection method
Methods
0.000
description
5
239000012153
distilled water
Substances
0.000
description
5
235000019441
ethanol
Nutrition
0.000
description
5
238000002415
sodium dodecyl sulfate polyacrylamide gel electrophoresis
Methods
0.000
description
5
150000008163
sugars
Chemical class
0.000
description
5
JOXIMZWYDAKGHI-UHFFFAOYSA-N
toluene-4-sulfonic acid
Chemical compound
CC1=CC=C(S(O)(=O)=O)C=C1
JOXIMZWYDAKGHI-UHFFFAOYSA-N
0.000
description
5
BVQVLAIMHVDZEL-UHFFFAOYSA-N
1-phenyl-1,2-propanedione
Chemical compound
CC(=O)C(=O)C1=CC=CC=C1
BVQVLAIMHVDZEL-UHFFFAOYSA-N
0.000
description
4
125000000954
2-hydroxyethyl group
Chemical group
[H]C([*])([H])C([H])([H])O[H]
0.000
description
4
241000196324
Embryophyta
Species
0.000
description
4
108090000790
Enzymes
Proteins
0.000
description
4
102000004190
Enzymes
Human genes
0.000
description
4
108010010803
Gelatin
Proteins
0.000
description
4
102000001554
Hemoglobins
Human genes
0.000
description
4
108010054147
Hemoglobins
Proteins
0.000
description
4
239000004472
Lysine
Substances
0.000
description
4
229920001213
Polysorbate 20
Polymers
0.000
description
4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N
Sodium azide
Chemical compound
[Na+].[N-]=[N+]=[N-]
PXIPVTKHYLBLMZ-UHFFFAOYSA-N
0.000
description
4
229920002472
Starch
Polymers
0.000
description
4
RAHZWNYVWXNFOC-UHFFFAOYSA-N
Sulphur dioxide
Chemical compound
O=S=O
RAHZWNYVWXNFOC-UHFFFAOYSA-N
0.000
description
4
239000002671
adjuvant
Substances
0.000
description
4
239000000427
antigen
Substances
0.000
description
4
102000036639
antigens
Human genes
0.000
description
4
108091007433
antigens
Proteins
0.000
description
4
OHDRQQURAXLVGJ-HLVWOLMTSA-N
azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid
Chemical compound
[NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC
OHDRQQURAXLVGJ-HLVWOLMTSA-N
0.000
description
4
238000011161
development
Methods
0.000
description
4
230000018109
developmental process
Effects
0.000
description
4
125000001495
ethyl group
Chemical group
[H]C([H])([H])C([H])([H])*
0.000
description
4
238000009472
formulation
Methods
0.000
description
4
239000008273
gelatin
Substances
0.000
description
4
229920000159
gelatin
Polymers
0.000
description
4
235000019322
gelatine
Nutrition
0.000
description
4
235000011852
gelatine desserts
Nutrition
0.000
description
4
201000001421
hyperglycemia
Diseases
0.000
description
4
HQKMJHAJHXVSDF-UHFFFAOYSA-L
magnesium stearate
Chemical compound
[Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O
HQKMJHAJHXVSDF-UHFFFAOYSA-L
0.000
description
4
239000011159
matrix material
Substances
0.000
description
4
125000001570
methylene group
Chemical group
[H]C([H])([*:1])[*:2]
0.000
description
4
229910052757
nitrogen
Inorganic materials
0.000
description
4
231100000252
nontoxic
Toxicity
0.000
description
4
230000003000
nontoxic effect
Effects
0.000
description
4
230000003287
optical effect
Effects
0.000
description
4
239000000256
polyoxyethylene sorbitan monolaurate
Substances
0.000
description
4
230000008707
rearrangement
Effects
0.000
description
4
239000012064
sodium phosphate buffer
Substances
0.000
description
4
239000008107
starch
Substances
0.000
description
4
235000019698
starch
Nutrition
0.000
description
4
239000006228
supernatant
Substances
0.000
description
4
238000004448
titration
Methods
0.000
description
4
230000000699
topical effect
Effects
0.000
description
4
OKBJVIVEFXPEOU-UHFFFAOYSA-N
1,2,3-trichloro-4-(2,3,6-trichlorophenyl)benzene
Chemical compound
ClC1=C(Cl)C(Cl)=CC=C1C1=C(Cl)C=CC(Cl)=C1Cl
OKBJVIVEFXPEOU-UHFFFAOYSA-N
0.000
description
3
UFELKDBLGZZXPN-UHFFFAOYSA-M
1,3-thiazol-3-ium-3-amine;2,4,6-trimethylbenzenesulfonate
Chemical compound
N[N+]=1C=CSC=1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
UFELKDBLGZZXPN-UHFFFAOYSA-M
0.000
description
3
VTQGDFUCAWBQKI-UHFFFAOYSA-N
2-(1,3-thiazol-3-ium-3-yl)acetamide;bromide
Chemical compound
[Br-].NC(=O)C[N+]=1C=CSC=1
VTQGDFUCAWBQKI-UHFFFAOYSA-N
0.000
description
3
BDQRQMLWZJQQKS-UHFFFAOYSA-M
2-(3-ethyl-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;bromide
Chemical compound
[Br-].CC[N+]1=CSC(CCO)=C1C
BDQRQMLWZJQQKS-UHFFFAOYSA-M
0.000
description
3
GGBKTOIWLNDJRN-UHFFFAOYSA-M
4-methyl-1,3-thiazol-3-ium-3-amine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=CSC=[N+]1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
GGBKTOIWLNDJRN-UHFFFAOYSA-M
0.000
description
3
OSNDILNVUHMSRT-UHFFFAOYSA-M
5-ethenyl-4-methyl-1,3-thiazol-3-ium-3-amine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=C(C=C)SC=[N+]1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
OSNDILNVUHMSRT-UHFFFAOYSA-M
0.000
description
3
XWCBMYNARPQWHF-UHFFFAOYSA-N
5-methyl-1,3-thiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=C[N+](N)=C(N)S1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
XWCBMYNARPQWHF-UHFFFAOYSA-N
0.000
description
3
208000024827
Alzheimer disease
Diseases
0.000
description
3
108010017384
Blood Proteins
Proteins
0.000
description
3
208000005156
Dehydration
Diseases
0.000
description
3
206010020751
Hypersensitivity
Diseases
0.000
description
3
102000006382
Ribonucleases
Human genes
0.000
description
3
108010083644
Ribonucleases
Proteins
0.000
description
3
HEMHJVSKTPXQMS-UHFFFAOYSA-M
Sodium hydroxide
Chemical compound
[OH-].[Na+]
HEMHJVSKTPXQMS-UHFFFAOYSA-M
0.000
description
3
238000009825
accumulation
Methods
0.000
description
3
125000003668
acetyloxy group
Chemical group
[H]C([H])([H])C(=O)O[*]
0.000
description
3
108010055267
advanced glycation end products-bovine serum albumin
Proteins
0.000
description
3
238000004458
analytical method
Methods
0.000
description
3
208000006673
asthma
Diseases
0.000
description
3
QQFYLZXBFWWJHR-UHFFFAOYSA-M
benzyl(triethyl)phosphanium;bromide
Chemical compound
[Br-].CC[P+](CC)(CC)CC1=CC=CC=C1
QQFYLZXBFWWJHR-UHFFFAOYSA-M
0.000
description
3
239000001058
brown pigment
Substances
0.000
description
3
125000002091
cationic group
Chemical group
0.000
description
3
YZIYKJHYYHPJIB-UUPCJSQJSA-N
chlorhexidine gluconate
Chemical compound
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1
YZIYKJHYYHPJIB-UUPCJSQJSA-N
0.000
description
3
230000001684
chronic effect
Effects
0.000
description
3
230000008878
coupling
Effects
0.000
description
3
238000010168
coupling process
Methods
0.000
description
3
238000005859
coupling reaction
Methods
0.000
description
3
230000018044
dehydration
Effects
0.000
description
3
238000006297
dehydration reaction
Methods
0.000
description
3
210000000585
glomerular basement membrane
Anatomy
0.000
description
3
210000003692
ilium
Anatomy
0.000
description
3
238000003018
immunoassay
Methods
0.000
description
3
230000000984
immunochemical effect
Effects
0.000
description
3
108010045069
keyhole-limpet hemocyanin
Proteins
0.000
description
3
230000001404
mediated effect
Effects
0.000
description
3
230000007170
pathology
Effects
0.000
description
3
230000037361
pathway
Effects
0.000
description
3
235000010486
polyoxyethylene sorbitan monolaurate
Nutrition
0.000
description
3
230000008569
process
Effects
0.000
description
3
210000002966
serum
Anatomy
0.000
description
3
210000004989
spleen cell
Anatomy
0.000
description
3
239000011550
stock solution
Substances
0.000
description
3
LSNNMFCWUKXFEE-UHFFFAOYSA-L
sulfite
Chemical class
[O-]S([O-])=O
LSNNMFCWUKXFEE-UHFFFAOYSA-L
0.000
description
3
239000000606
toothpaste
Substances
0.000
description
3
HYBCFWFWKXJYFT-UHFFFAOYSA-N
1,3-benzothiazole-2,6-diamine
Chemical compound
C1=C(N)C=C2SC(N)=NC2=C1
HYBCFWFWKXJYFT-UHFFFAOYSA-N
0.000
description
2
JMMMTDNFCAEPLK-UHFFFAOYSA-N
2-(2,3-diamino-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=C(CCO)SC(N)=[N+]1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
JMMMTDNFCAEPLK-UHFFFAOYSA-N
0.000
description
2
GDNOYVMHHMSZJV-UHFFFAOYSA-M
2-(3,4-dimethyl-1,3-thiazol-3-ium-5-yl)ethanol;iodide
Chemical compound
[I-].CC1=C(CCO)SC=[N+]1C
GDNOYVMHHMSZJV-UHFFFAOYSA-M
0.000
description
2
ZNTMUCAOGIQELW-UHFFFAOYSA-N
2-(4-methyl-1,3-thiazol-3-ium-3-yl)acetamide;bromide
Chemical compound
[Br-].CC1=CSC=[N+]1CC(N)=O
ZNTMUCAOGIQELW-UHFFFAOYSA-N
0.000
description
2
FNHVHCNRNHQLBY-UHFFFAOYSA-N
2-(5-methyl-1,3-thiazol-3-ium-3-yl)acetamide;bromide
Chemical compound
[Br-].CC1=C[N+](CC(N)=O)=CS1
FNHVHCNRNHQLBY-UHFFFAOYSA-N
0.000
description
2
DMTXJIZFXUYFRJ-UHFFFAOYSA-M
2-[3-[(2,6-dichlorophenyl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride
Chemical compound
[Cl-].CC1=C(CCO)SC=[N+]1CC1=C(Cl)C=CC=C1Cl
DMTXJIZFXUYFRJ-UHFFFAOYSA-M
0.000
description
2
XFGDLZFXBVHRES-UHFFFAOYSA-M
2-[3-[(3-methoxyphenyl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride
Chemical compound
[Cl-].COC1=CC=CC(C[N+]=2C(=C(CCO)SC=2)C)=C1
XFGDLZFXBVHRES-UHFFFAOYSA-M
0.000
description
2
MKHUPLOXJALSDR-UHFFFAOYSA-M
2-[4-methyl-3-[(2-nitrophenyl)methyl]-1,3-thiazol-3-ium-5-yl]ethanol;bromide
Chemical compound
[Br-].CC1=C(CCO)SC=[N+]1CC1=CC=CC=C1[N+]([O-])=O
MKHUPLOXJALSDR-UHFFFAOYSA-M
0.000
description
2
LPDYGEYQKFCXNE-UHFFFAOYSA-N
4,5-dihydro-1,3-thiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
NC1=[N+](N)CCS1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
LPDYGEYQKFCXNE-UHFFFAOYSA-N
0.000
description
2
VHKIQENFFFOYRG-UHFFFAOYSA-N
4,5-dimethyl-1,3-thiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC=1SC(N)=[N+](N)C=1C.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
VHKIQENFFFOYRG-UHFFFAOYSA-N
0.000
description
2
MSGVTOPEJUTXQS-UHFFFAOYSA-N
4-chloro-1,3-benzothiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
C1=CC(Cl)=C2[N+](N)=C(N)SC2=C1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
MSGVTOPEJUTXQS-UHFFFAOYSA-N
0.000
description
2
JEJLGDZQGXNRMY-UHFFFAOYSA-N
6-chloro-1,3-benzothiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
ClC1=CC=C2[N+](N)=C(N)SC2=C1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
JEJLGDZQGXNRMY-UHFFFAOYSA-N
0.000
description
2
208000037259
Amyloid Plaque
Diseases
0.000
description
2
102000004506
Blood Proteins
Human genes
0.000
description
2
GAWIXWVDTYZWAW-UHFFFAOYSA-N
C[CH]O
Chemical group
C[CH]O
GAWIXWVDTYZWAW-UHFFFAOYSA-N
0.000
description
2
102000016942
Elastin
Human genes
0.000
description
2
108010014258
Elastin
Proteins
0.000
description
2
PEDCQBHIVMGVHV-UHFFFAOYSA-N
Glycerine
Chemical compound
OCC(O)CO
PEDCQBHIVMGVHV-UHFFFAOYSA-N
0.000
description
2
WGCNASOHLSPBMP-UHFFFAOYSA-N
Glycolaldehyde
Chemical compound
OCC=O
WGCNASOHLSPBMP-UHFFFAOYSA-N
0.000
description
2
108060003951
Immunoglobulin
Proteins
0.000
description
2
206010035226
Plasma cell myeloma
Diseases
0.000
description
2
DBMJMQXJHONAFJ-UHFFFAOYSA-M
Sodium laurylsulphate
Chemical compound
[Na+].CCCCCCCCCCCCOS([O-])(=O)=O
DBMJMQXJHONAFJ-UHFFFAOYSA-M
0.000
description
2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N
Streptozotocin
Natural products
O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O
ZSJLQEPLLKMAKR-UHFFFAOYSA-N
0.000
description
2
125000003282
alkyl amino group
Chemical group
0.000
description
2
230000007815
allergy
Effects
0.000
description
2
150000001412
amines
Chemical class
0.000
description
2
150000001413
amino acids
Chemical class
0.000
description
2
239000004599
antimicrobial
Substances
0.000
description
2
229960000686
benzalkonium chloride
Drugs
0.000
description
2
WPYMKLBDIGXBTP-UHFFFAOYSA-N
benzoic acid
Chemical compound
OC(=O)C1=CC=CC=C1
WPYMKLBDIGXBTP-UHFFFAOYSA-N
0.000
description
2
IOJUPLGTWVMSFF-UHFFFAOYSA-N
benzothiazole
Chemical compound
C1=CC=C2SC=NC2=C1
IOJUPLGTWVMSFF-UHFFFAOYSA-N
0.000
description
2
CADWTSSKOVRVJC-UHFFFAOYSA-N
benzyl(dimethyl)azanium;chloride
Chemical compound
[Cl-].C[NH+](C)CC1=CC=CC=C1
CADWTSSKOVRVJC-UHFFFAOYSA-N
0.000
description
2
230000000903
blocking effect
Effects
0.000
description
2
210000000988
bone and bone
Anatomy
0.000
description
2
210000004027
cell
Anatomy
0.000
description
2
229960003333
chlorhexidine gluconate
Drugs
0.000
description
2
238000001816
cooling
Methods
0.000
description
2
230000002939
deleterious effect
Effects
0.000
description
2
230000001419
dependent effect
Effects
0.000
description
2
239000008121
dextrose
Substances
0.000
description
2
125000004663
dialkyl amino group
Chemical group
0.000
description
2
230000004069
differentiation
Effects
0.000
description
2
230000029087
digestion
Effects
0.000
description
2
239000003937
drug carrier
Substances
0.000
description
2
238000002651
drug therapy
Methods
0.000
description
2
229920002549
elastin
Polymers
0.000
description
2
238000001962
electrophoresis
Methods
0.000
description
2
125000002534
ethynyl group
Chemical group
[H]C#C*
0.000
description
2
150000004820
halides
Chemical class
0.000
description
2
230000002163
immunogen
Effects
0.000
description
2
102000018358
immunoglobulin
Human genes
0.000
description
2
238000007689
inspection
Methods
0.000
description
2
230000003993
interaction
Effects
0.000
description
2
238000007918
intramuscular administration
Methods
0.000
description
2
239000007928
intraperitoneal injection
Substances
0.000
description
2
238000001990
intravenous administration
Methods
0.000
description
2
239000006210
lotion
Substances
0.000
description
2
235000019359
magnesium stearate
Nutrition
0.000
description
2
AUHZEENZYGFFBQ-UHFFFAOYSA-N
mesitylene
Substances
CC1=CC(C)=CC(C)=C1
AUHZEENZYGFFBQ-UHFFFAOYSA-N
0.000
description
2
BDAGIHXWWSANSR-UHFFFAOYSA-N
methanoic acid
Natural products
OC=O
BDAGIHXWWSANSR-UHFFFAOYSA-N
0.000
description
2
LXEFEISDDNNXSI-UHFFFAOYSA-M
methyl 2-(1,3-benzothiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].C1=CC=C2[N+](CC(=O)OC)=CSC2=C1
LXEFEISDDNNXSI-UHFFFAOYSA-M
0.000
description
2
KQMCZYWNZDCUIU-UHFFFAOYSA-M
methyl 2-(1,3-thiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]=1C=CSC=1
KQMCZYWNZDCUIU-UHFFFAOYSA-M
0.000
description
2
QBJKXUXUPMSXFG-UHFFFAOYSA-M
methyl 2-(5-methyl-1,3-thiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]1=CSC(C)=C1
QBJKXUXUPMSXFG-UHFFFAOYSA-M
0.000
description
2
201000000050
myeloid neoplasm
Diseases
0.000
description
2
239000013642
negative control
Substances
0.000
description
2
210000005036
nerve
Anatomy
0.000
description
2
230000007935
neutral effect
Effects
0.000
description
2
239000012038
nucleophile
Substances
0.000
description
2
210000000056
organ
Anatomy
0.000
description
2
239000008188
pellet
Substances
0.000
description
2
239000008363
phosphate buffer
Substances
0.000
description
2
230000004962
physiological condition
Effects
0.000
description
2
239000002798
polar solvent
Substances
0.000
description
2
229920000642
polymer
Polymers
0.000
description
2
230000002265
prevention
Effects
0.000
description
2
230000009467
reduction
Effects
0.000
description
2
230000002829
reductive effect
Effects
0.000
description
2
238000010992
reflux
Methods
0.000
description
2
CVHZOJJKTDOEJC-UHFFFAOYSA-N
saccharin
Chemical compound
C1=CC=C2C(=O)NS(=O)(=O)C2=C1
CVHZOJJKTDOEJC-UHFFFAOYSA-N
0.000
description
2
238000013207
serial dilution
Methods
0.000
description
2
239000011734
sodium
Substances
0.000
description
2
235000019333
sodium laurylsulphate
Nutrition
0.000
description
2
239000001488
sodium phosphate
Substances
0.000
description
2
229910000162
sodium phosphate
Inorganic materials
0.000
description
2
235000011008
sodium phosphates
Nutrition
0.000
description
2
241000894007
species
Species
0.000
description
2
238000010186
staining
Methods
0.000
description
2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N
streptozocin
Chemical compound
O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O
ZSJLQEPLLKMAKR-GKHCUFPYSA-N
0.000
description
2
229960001052
streptozocin
Drugs
0.000
description
2
238000003786
synthesis reaction
Methods
0.000
description
2
210000001519
tissue
Anatomy
0.000
description
2
230000036344
tooth staining
Effects
0.000
description
2
RYFMWSXOAZQYPI-UHFFFAOYSA-K
trisodium phosphate
Chemical compound
[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O
RYFMWSXOAZQYPI-UHFFFAOYSA-K
0.000
description
2
NPLHAQKMFXRMBM-UHFFFAOYSA-N
1,3-benzothiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
C1=CC=C2[N+](N)=C(N)SC2=C1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
NPLHAQKMFXRMBM-UHFFFAOYSA-N
0.000
description
1
DTOUUUZOYKYHEP-UHFFFAOYSA-N
1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine
Chemical compound
CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1
DTOUUUZOYKYHEP-UHFFFAOYSA-N
0.000
description
1
YYRBESPQXYZSKI-UHFFFAOYSA-M
1-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]-3,3-dimethylbutan-2-one;bromide
Chemical compound
[Br-].CC1=C(CCO)SC=[N+]1CC(=O)C(C)(C)C
YYRBESPQXYZSKI-UHFFFAOYSA-M
0.000
description
1
LXFQSRIDYRFTJW-UHFFFAOYSA-N
2,4,6-trimethylbenzenesulfonic acid
Chemical class
CC1=CC(C)=C(S(O)(=O)=O)C(C)=C1
LXFQSRIDYRFTJW-UHFFFAOYSA-N
0.000
description
1
FVTNECUBUADHND-UHFFFAOYSA-N
2-(1,3-benzothiazol-3-ium-2-yl)-1-phenylethanone;bromide
Chemical compound
[Br-].[NH+]=1C2=CC=CC=C2SC=1CC(=O)C1=CC=CC=C1
FVTNECUBUADHND-UHFFFAOYSA-N
0.000
description
1
MIPPUJJTHYPZQM-UHFFFAOYSA-M
2-(1,3-benzothiazol-3-ium-3-yl)-1-phenylethanone;bromide
Chemical compound
[Br-].C=1SC2=CC=CC=C2[N+]=1CC(=O)C1=CC=CC=C1
MIPPUJJTHYPZQM-UHFFFAOYSA-M
0.000
description
1
WJOGBWXSYKASNP-UHFFFAOYSA-N
2-(2-amino-1,3-thiazol-3-ium-3-yl)acetamide;bromide
Chemical compound
[Br-].NC(=O)C[N+]=1C=CSC=1N
WJOGBWXSYKASNP-UHFFFAOYSA-N
0.000
description
1
MAVHUYMYIPOYCL-UHFFFAOYSA-N
2-(2-methyl-1,3-thiazol-5-yl)ethanol
Chemical compound
CC1=NC=C(CCO)S1
MAVHUYMYIPOYCL-UHFFFAOYSA-N
0.000
description
1
HIJZESFLFDMKSD-UHFFFAOYSA-M
2-(3-amino-4-methyl-1,3-thiazol-3-ium-5-yl)ethyl acetate;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC(=O)OCCC=1SC=[N+](N)C=1C.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
HIJZESFLFDMKSD-UHFFFAOYSA-M
0.000
description
1
YNLYMNLRSJBRGZ-UHFFFAOYSA-N
2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)acetamide;bromide
Chemical compound
[Br-].CC=1SC=[N+](CC(N)=O)C=1C
YNLYMNLRSJBRGZ-UHFFFAOYSA-N
0.000
description
1
OAUPLRNBXYGSIO-UHFFFAOYSA-M
2-(4-methyl-3-prop-2-ynyl-4,5-dihydro-1,3-thiazol-3-ium-5-yl)ethanol;bromide
Chemical compound
[Br-].CC1C(CCO)SC=[N+]1CC#C
OAUPLRNBXYGSIO-UHFFFAOYSA-M
0.000
description
1
KMXIAGGLPIKMTM-UHFFFAOYSA-M
2-(5-methyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;bromide
Chemical compound
[Br-].S1C(C)=C[N+](CC(=O)C=2C=CC=CC=2)=C1
KMXIAGGLPIKMTM-UHFFFAOYSA-M
0.000
description
1
LWSHSBUEEJYWSH-UHFFFAOYSA-N
2-[3-(2-amino-2-oxoethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl acetate;bromide
Chemical compound
[Br-].CC(=O)OCCC=1SC=[N+](CC(N)=O)C=1C
LWSHSBUEEJYWSH-UHFFFAOYSA-N
0.000
description
1
WLAMNBDJUVNPJU-UHFFFAOYSA-N
2-methylbutyric acid
Chemical compound
CCC(C)C(O)=O
WLAMNBDJUVNPJU-UHFFFAOYSA-N
0.000
description
1
LEDUZYMUGFQUTN-UHFFFAOYSA-L
3,3-dimethyl-1-(1,3-thiazol-3-ium-3-yl)butan-2-one 1-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]-3,3-dimethylbutan-2-one dibromide
Chemical compound
[Br-].C(C)(C)(C)C(C[N+]1=CSC(=C1C)CCO)=O.[Br-].C(C)(C)(C)C(C[N+]1=CSC=C1)=O
LEDUZYMUGFQUTN-UHFFFAOYSA-L
0.000
description
1
VYPGQZSMSHEDJJ-UHFFFAOYSA-M
3,3-dimethyl-1-(1,3-thiazol-3-ium-3-yl)butan-2-one;bromide
Chemical compound
[Br-].CC(C)(C)C(=O)C[N+]=1C=CSC=1
VYPGQZSMSHEDJJ-UHFFFAOYSA-M
0.000
description
1
125000006275
3-bromophenyl group
Chemical group
[H]C1=C([H])C(Br)=C([H])C(*)=C1[H]
0.000
description
1
ZGCHLOWZNKRZSN-NTSWFWBYSA-N
3-deoxyglucosone
Chemical compound
OC[C@@H](O)[C@@H](O)CC(=O)C=O
ZGCHLOWZNKRZSN-NTSWFWBYSA-N
0.000
description
1
UHPMJDGOAZMIID-UHFFFAOYSA-N
3-deoxyglucosone
Natural products
OCC1OC(O)C(=O)CC1O
UHPMJDGOAZMIID-UHFFFAOYSA-N
0.000
description
1
PCDWFBFHIIKIPM-UHFFFAOYSA-N
3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid
Chemical compound
C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1
PCDWFBFHIIKIPM-UHFFFAOYSA-N
0.000
description
1
125000004207
3-methoxyphenyl group
Chemical group
[H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H]
0.000
description
1
MAPYAGFBSZSYSY-UHFFFAOYSA-M
3-prop-2-ynyl-1,3-thiazol-3-ium;bromide
Chemical compound
[Br-].C#CC[N+]=1C=CSC=1
MAPYAGFBSZSYSY-UHFFFAOYSA-M
0.000
description
1
COXYDOJLFYPMSM-UHFFFAOYSA-M
3-prop-2-ynyl-4,5-dihydro-1,3-thiazol-3-ium;bromide
Chemical compound
[Br-].C#CC[N+]1=CSCC1
COXYDOJLFYPMSM-UHFFFAOYSA-M
0.000
description
1
UWSONZCNXUSTKW-UHFFFAOYSA-N
4,5-Dimethylthiazole
Chemical compound
CC=1N=CSC=1C
UWSONZCNXUSTKW-UHFFFAOYSA-N
0.000
description
1
FGLVXXQNICMYQQ-UHFFFAOYSA-N
4,5-dimethyl-1,3-thiazol-3-ium-3-amine
Chemical compound
CC=1SC=[N+](N)C=1C
FGLVXXQNICMYQQ-UHFFFAOYSA-N
0.000
description
1
BLYJGWZLANJOIF-UHFFFAOYSA-M
4,5-dimethyl-1,3-thiazol-3-ium-3-amine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC=1SC=[N+](N)C=1C.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
BLYJGWZLANJOIF-UHFFFAOYSA-M
0.000
description
1
MYKHDUNRUFKQFC-UHFFFAOYSA-M
4,5-dimethyl-3-prop-2-ynyl-1,3-thiazol-3-ium;bromide
Chemical compound
[Br-].CC=1SC=[N+](CC#C)C=1C
MYKHDUNRUFKQFC-UHFFFAOYSA-M
0.000
description
1
WWUWPASTGMNPME-UHFFFAOYSA-M
4,5-dimethyl-3-prop-2-ynyl-4,5-dihydro-1,3-thiazol-3-ium;bromide
Chemical compound
[Br-].CC1SC=[N+](CC#C)C1C
WWUWPASTGMNPME-UHFFFAOYSA-M
0.000
description
1
OSWFIVFLDKOXQC-UHFFFAOYSA-N
4-(3-methoxyphenyl)aniline
Chemical compound
COC1=CC=CC(C=2C=CC(N)=CC=2)=C1
OSWFIVFLDKOXQC-UHFFFAOYSA-N
0.000
description
1
XZKIHKMTEMTJQX-UHFFFAOYSA-N
4-Nitrophenyl Phosphate
Chemical compound
OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1
XZKIHKMTEMTJQX-UHFFFAOYSA-N
0.000
description
1
125000004800
4-bromophenyl group
Chemical group
[H]C1=C([H])C(*)=C([H])C([H])=C1Br
0.000
description
1
FIUVVGSVARXOJZ-UHFFFAOYSA-N
4-methyl-1,3-thiazol-3-ium-2,3-diamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CC1=CSC(N)=[N+]1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
FIUVVGSVARXOJZ-UHFFFAOYSA-N
0.000
description
1
SEYSVHPGRPMUDZ-UHFFFAOYSA-M
4-methyl-3-prop-2-ynyl-1,3-thiazol-3-ium;bromide
Chemical compound
[Br-].CC1=CSC=[N+]1CC#C
SEYSVHPGRPMUDZ-UHFFFAOYSA-M
0.000
description
1
IUBALRWYWJCAQX-UHFFFAOYSA-M
4-methyl-3-prop-2-ynyl-4,5-dihydro-1,3-thiazol-3-ium;bromide
Chemical compound
[Br-].CC1CSC=[N+]1CC#C
IUBALRWYWJCAQX-UHFFFAOYSA-M
0.000
description
1
RQNZQVHYCPFEEQ-UHFFFAOYSA-N
4-n,5-n-dimethyl-1,3-thiazol-3-ium-3,4,5-triamine
Chemical compound
CNC=1SC=[N+](N)C=1NC
RQNZQVHYCPFEEQ-UHFFFAOYSA-N
0.000
description
1
UWTDCWIBRQSPCT-UHFFFAOYSA-M
4-n,5-n-dimethyl-1,3-thiazol-3-ium-3,4,5-triamine;2,4,6-trimethylbenzenesulfonate
Chemical compound
CNC=1SC=[N+](N)C=1NC.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
UWTDCWIBRQSPCT-UHFFFAOYSA-M
0.000
description
1
HRPVXLWXLXDGHG-UHFFFAOYSA-N
Acrylamide
Chemical compound
NC(=O)C=C
HRPVXLWXLXDGHG-UHFFFAOYSA-N
0.000
description
1
102000009027
Albumins
Human genes
0.000
description
1
108010088751
Albumins
Proteins
0.000
description
1
240000003291
Armoracia rusticana
Species
0.000
description
1
235000011330
Armoracia rusticana
Nutrition
0.000
description
1
241000894006
Bacteria
Species
0.000
description
1
239000005711
Benzoic acid
Substances
0.000
description
1
229920002799
BoPET
Polymers
0.000
description
1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L
Brilliant Blue
Chemical compound
[Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L
0.000
description
1
125000000041
C6-C10 aryl group
Chemical group
0.000
description
1
VEXZGXHMUGYJMC-UHFFFAOYSA-M
Chloride anion
Chemical compound
[Cl-]
VEXZGXHMUGYJMC-UHFFFAOYSA-M
0.000
description
1
241000699800
Cricetinae
Species
0.000
description
1
FBPFZTCFMRRESA-FSIIMWSLSA-N
D-Glucitol
Natural products
OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO
FBPFZTCFMRRESA-FSIIMWSLSA-N
0.000
description
1
FBPFZTCFMRRESA-KVTDHHQDSA-N
D-Mannitol
Chemical compound
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
FBPFZTCFMRRESA-KVTDHHQDSA-N
0.000
description
1
MNQZXJOMYWMBOU-VKHMYHEASA-N
D-glyceraldehyde
Chemical compound
OC[C@@H](O)C=O
MNQZXJOMYWMBOU-VKHMYHEASA-N
0.000
description
1
HMFHBZSHGGEWLO-SOOFDHNKSA-N
D-ribofuranose
Chemical compound
OC[C@H]1OC(O)[C@H](O)[C@@H]1O
HMFHBZSHGGEWLO-SOOFDHNKSA-N
0.000
description
1
206010012289
Dementia
Diseases
0.000
description
1
RTZKZFJDLAIYFH-UHFFFAOYSA-N
Diethyl ether
Chemical compound
CCOCC
RTZKZFJDLAIYFH-UHFFFAOYSA-N
0.000
description
1
241001269524
Dura
Species
0.000
description
1
238000012286
ELISA Assay
Methods
0.000
description
1
229930091371
Fructose
Natural products
0.000
description
1
239000005715
Fructose
Substances
0.000
description
1
RFSUNEUAIZKAJO-ARQDHWQXSA-N
Fructose
Chemical compound
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O
RFSUNEUAIZKAJO-ARQDHWQXSA-N
0.000
description
1
241000287828
Gallus gallus
Species
0.000
description
1
108060003393
Granulin
Proteins
0.000
description
1
241000282412
Homo
Species
0.000
description
1
229920002153
Hydroxypropyl cellulose
Polymers
0.000
description
1
DGAQECJNVWCQMB-PUAWFVPOSA-M
Ilexoside XXIX
Chemical compound
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+]
DGAQECJNVWCQMB-PUAWFVPOSA-M
0.000
description
1
GUBGYTABKSRVRQ-QKKXKWKRSA-N
Lactose
Natural products
OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
GUBGYTABKSRVRQ-QKKXKWKRSA-N
0.000
description
1
102000004895
Lipoproteins
Human genes
0.000
description
1
108090001030
Lipoproteins
Proteins
0.000
description
1
229930195725
Mannitol
Natural products
0.000
description
1
244000024873
Mentha crispa
Species
0.000
description
1
235000014749
Mentha crispa
Nutrition
0.000
description
1
241001529936
Murinae
Species
0.000
description
1
241000699670
Mus sp.
Species
0.000
description
1
239000005041
Mylar™
Substances
0.000
description
1
229920001214
Polysorbate 60
Polymers
0.000
description
1
206010063493
Premature ageing
Diseases
0.000
description
1
208000032038
Premature aging
Diseases
0.000
description
1
206010057430
Retinal injury
Diseases
0.000
description
1
PYMYPHUHKUWMLA-LMVFSUKVSA-N
Ribose
Natural products
OC[C@@H](O)[C@@H](O)[C@@H](O)C=O
PYMYPHUHKUWMLA-LMVFSUKVSA-N
0.000
description
1
FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound
[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
1
235000021355
Stearic acid
Nutrition
0.000
description
1
101710172711
Structural protein
Proteins
0.000
description
1
LSNNMFCWUKXFEE-UHFFFAOYSA-N
Sulfurous acid
Chemical compound
OS(O)=O
LSNNMFCWUKXFEE-UHFFFAOYSA-N
0.000
description
1
102000009843
Thyroglobulin
Human genes
0.000
description
1
108010034949
Thyroglobulin
Proteins
0.000
description
1
101710086987
X protein
Proteins
0.000
description
1
HNXRBAUXGWMZCV-UHFFFAOYSA-N
[Br-].CC1=C[N+](N)=C(N)S1.C1=CC=C2SC=[NH+]C2=C1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
Chemical compound
[Br-].CC1=C[N+](N)=C(N)S1.C1=CC=C2SC=[NH+]C2=C1.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1
HNXRBAUXGWMZCV-UHFFFAOYSA-N
0.000
description
1
FWOHSZSRFKYTRW-UHFFFAOYSA-N
[Br-].CC1=[NH+]C=C(CCO)S1
Chemical compound
[Br-].CC1=[NH+]C=C(CCO)S1
FWOHSZSRFKYTRW-UHFFFAOYSA-N
0.000
description
1
230000002159
abnormal effect
Effects
0.000
description
1
230000005856
abnormality
Effects
0.000
description
1
238000002835
absorbance
Methods
0.000
description
1
239000002253
acid
Substances
0.000
description
1
230000009471
action
Effects
0.000
description
1
239000013543
active substance
Substances
0.000
description
1
230000002776
aggregation
Effects
0.000
description
1
238000004220
aggregation
Methods
0.000
description
1
LFVVNPBBFUSSHL-UHFFFAOYSA-N
alexidine
Chemical compound
CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC
LFVVNPBBFUSSHL-UHFFFAOYSA-N
0.000
description
1
229950010221
alexidine
Drugs
0.000
description
1
208000026935
allergic disease
Diseases
0.000
description
1
208000030961
allergic reaction
Diseases
0.000
description
1
HMFHBZSHGGEWLO-UHFFFAOYSA-N
alpha-D-Furanose-Ribose
Natural products
OCC1OC(O)C(O)C1O
HMFHBZSHGGEWLO-UHFFFAOYSA-N
0.000
description
1
WQZGKKKJIJFFOK-PHYPRBDBSA-N
alpha-D-galactose
Chemical compound
OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O
WQZGKKKJIJFFOK-PHYPRBDBSA-N
0.000
description
1
HSFWRNGVRCDJHI-UHFFFAOYSA-N
alpha-acetylene
Chemical group
C#C
HSFWRNGVRCDJHI-UHFFFAOYSA-N
0.000
description
1
229940037003
alum
Drugs
0.000
description
1
238000010171
animal model
Methods
0.000
description
1
230000002421
anti-septic effect
Effects
0.000
description
1
229940064004
antiseptic throat preparations
Drugs
0.000
description
1
238000013459
approach
Methods
0.000
description
1
239000007864
aqueous solution
Substances
0.000
description
1
210000001367
artery
Anatomy
0.000
description
1
238000000211
autoradiogram
Methods
0.000
description
1
230000001580
bacterial effect
Effects
0.000
description
1
210000002469
basement membrane
Anatomy
0.000
description
1
235000010233
benzoic acid
Nutrition
0.000
description
1
238000007068
beta-elimination reaction
Methods
0.000
description
1
239000012472
biological sample
Substances
0.000
description
1
230000037396
body weight
Effects
0.000
description
1
210000004556
brain
Anatomy
0.000
description
1
235000012745
brilliant blue FCF
Nutrition
0.000
description
1
239000004161
brilliant blue FCF
Substances
0.000
description
1
125000001246
bromo group
Chemical group
Br*
0.000
description
1
125000004799
bromophenyl group
Chemical group
0.000
description
1
239000008366
buffered solution
Substances
0.000
description
1
125000000484
butyl group
Chemical group
[H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H]
0.000
description
1
XAAHAAMILDNBPS-UHFFFAOYSA-L
calcium hydrogenphosphate dihydrate
Chemical compound
O.O.[Ca+2].OP([O-])([O-])=O
XAAHAAMILDNBPS-UHFFFAOYSA-L
0.000
description
1
239000002775
capsule
Substances
0.000
description
1
150000001718
carbodiimides
Chemical class
0.000
description
1
CREMABGTGYGIQB-UHFFFAOYSA-N
carbon carbon
Chemical compound
C.C
CREMABGTGYGIQB-UHFFFAOYSA-N
0.000
description
1
239000011203
carbon fibre reinforced carbon
Substances
0.000
description
1
150000001728
carbonyl compounds
Chemical class
0.000
description
1
239000005018
casein
Substances
0.000
description
1
BECPQYXYKAMYBN-UHFFFAOYSA-N
casein, tech.
Chemical compound
NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1
BECPQYXYKAMYBN-UHFFFAOYSA-N
0.000
description
1
235000021240
caseins
Nutrition
0.000
description
1
238000006555
catalytic reaction
Methods
0.000
description
1
210000000170
cell membrane
Anatomy
0.000
description
1
229920002678
cellulose
Polymers
0.000
description
1
YMKDRGPMQRFJGP-UHFFFAOYSA-M
cetylpyridinium chloride
Chemical compound
[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1
YMKDRGPMQRFJGP-UHFFFAOYSA-M
0.000
description
1
229960001927
cetylpyridinium chloride
Drugs
0.000
description
1
235000013330
chicken meat
Nutrition
0.000
description
1
238000010367
cloning
Methods
0.000
description
1
238000007398
colorimetric assay
Methods
0.000
description
1
230000002860
competitive effect
Effects
0.000
description
1
229940125782
compound 2
Drugs
0.000
description
1
238000007906
compression
Methods
0.000
description
1
230000006835
compression
Effects
0.000
description
1
238000009833
condensation
Methods
0.000
description
1
230000005494
condensation
Effects
0.000
description
1
210000002808
connective tissue
Anatomy
0.000
description
1
239000000470
constituent
Substances
0.000
description
1
238000010411
cooking
Methods
0.000
description
1
125000004122
cyclic group
Chemical group
0.000
description
1
238000003936
denaturing gel electrophoresis
Methods
0.000
description
1
210000001315
dental pellicle
Anatomy
0.000
description
1
230000036576
dermal application
Effects
0.000
description
1
239000003599
detergent
Substances
0.000
description
1
238000000502
dialysis
Methods
0.000
description
1
229940061607
dibasic sodium phosphate
Drugs
0.000
description
1
125000004989
dicarbonyl group
Chemical group
0.000
description
1
235000021245
dietary protein
Nutrition
0.000
description
1
238000009792
diffusion process
Methods
0.000
description
1
239000012470
diluted sample
Substances
0.000
description
1
238000007865
diluting
Methods
0.000
description
1
239000003085
diluting agent
Substances
0.000
description
1
BNIILDVGGAEEIG-UHFFFAOYSA-L
disodium hydrogen phosphate
Chemical compound
[Na+].[Na+].OP([O-])([O-])=O
BNIILDVGGAEEIG-UHFFFAOYSA-L
0.000
description
1
239000006185
dispersion
Substances
0.000
description
1
239000002552
dosage form
Substances
0.000
description
1
230000008030
elimination
Effects
0.000
description
1
238000003379
elimination reaction
Methods
0.000
description
1
210000003038
endothelium
Anatomy
0.000
description
1
238000005516
engineering process
Methods
0.000
description
1
230000007515
enzymatic degradation
Effects
0.000
description
1
238000011156
evaluation
Methods
0.000
description
1
239000000835
fiber
Substances
0.000
description
1
230000004992
fission
Effects
0.000
description
1
125000001153
fluoro group
Chemical group
F*
0.000
description
1
235000019249
food preservative
Nutrition
0.000
description
1
239000005452
food preservative
Substances
0.000
description
1
235000019253
formic acid
Nutrition
0.000
description
1
235000021022
fresh fruits
Nutrition
0.000
description
1
230000004927
fusion
Effects
0.000
description
1
229930182830
galactose
Natural products
0.000
description
1
238000001502
gel electrophoresis
Methods
0.000
description
1
235000011187
glycerol
Nutrition
0.000
description
1
238000005469
granulation
Methods
0.000
description
1
230000003179
granulation
Effects
0.000
description
1
210000003128
head
Anatomy
0.000
description
1
229960004867
hexetidine
Drugs
0.000
description
1
125000004051
hexyl group
Chemical group
[H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])*
0.000
description
1
125000003707
hexyloxy group
Chemical group
[H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O*
0.000
description
1
239000001863
hydroxypropyl cellulose
Substances
0.000
description
1
235000010977
hydroxypropyl cellulose
Nutrition
0.000
description
1
238000003384
imaging method
Methods
0.000
description
1
230000001900
immune effect
Effects
0.000
description
1
229940127121
immunoconjugate
Drugs
0.000
description
1
239000007927
intramuscular injection
Substances
0.000
description
1
238000007912
intraperitoneal administration
Methods
0.000
description
1
125000002346
iodo group
Chemical group
I*
0.000
description
1
238000002955
isolation
Methods
0.000
description
1
208000017169
kidney disease
Diseases
0.000
description
1
239000008101
lactose
Substances
0.000
description
1
210000003041
ligament
Anatomy
0.000
description
1
230000007774
longterm
Effects
0.000
description
1
229920002521
macromolecule
Polymers
0.000
description
1
239000000594
mannitol
Substances
0.000
description
1
235000010355
mannitol
Nutrition
0.000
description
1
238000005259
measurement
Methods
0.000
description
1
239000001525
mentha piperita l. herb oil
Substances
0.000
description
1
230000002503
metabolic effect
Effects
0.000
description
1
JBUANRJAKMFBJY-UHFFFAOYSA-N
methyl 2-(2-amino-1,3-benzothiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].C1=CC=C2[N+](CC(=O)OC)=C(N)SC2=C1
JBUANRJAKMFBJY-UHFFFAOYSA-N
0.000
description
1
JCWDWGMLWXAQSR-UHFFFAOYSA-N
methyl 2-(2-amino-1,3-thiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]=1C=CSC=1N
JCWDWGMLWXAQSR-UHFFFAOYSA-N
0.000
description
1
NUUXZMRACXQGRI-UHFFFAOYSA-M
methyl 2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]1=CSC(C)=C1C
NUUXZMRACXQGRI-UHFFFAOYSA-M
0.000
description
1
ULWBZNFCLKNXCC-UHFFFAOYSA-M
methyl 2-(4-methyl-1,3-thiazol-3-ium-3-yl)acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]1=CSC=C1C
ULWBZNFCLKNXCC-UHFFFAOYSA-M
0.000
description
1
QIGVOANCAIAQTR-UHFFFAOYSA-M
methyl 2-[5-(2-acetyloxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]1=CSC(CCOC(C)=O)=C1C
QIGVOANCAIAQTR-UHFFFAOYSA-M
0.000
description
1
SBQUSKGDTVGAGY-UHFFFAOYSA-M
methyl 2-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]acetate;bromide
Chemical compound
[Br-].COC(=O)C[N+]1=CSC(CCO)=C1C
SBQUSKGDTVGAGY-UHFFFAOYSA-M
0.000
description
1
YDCHPLOFQATIDS-UHFFFAOYSA-N
methyl 2-bromoacetate
Chemical compound
COC(=O)CBr
YDCHPLOFQATIDS-UHFFFAOYSA-N
0.000
description
1
238000002156
mixing
Methods
0.000
description
1
230000004048
modification
Effects
0.000
description
1
238000012986
modification
Methods
0.000
description
1
229940045641
monobasic sodium phosphate
Drugs
0.000
description
1
229910000403
monosodium phosphate
Inorganic materials
0.000
description
1
235000019799
monosodium phosphate
Nutrition
0.000
description
1
230000004660
morphological change
Effects
0.000
description
1
229940051866
mouthwash
Drugs
0.000
description
1
FZRGMMREPLSWOR-UHFFFAOYSA-M
n,n-dibutyl-2-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]acetamide;bromide
Chemical compound
[Br-].CCCCN(CCCC)C(=O)C[N+]1=CSC(CCO)=C1C
FZRGMMREPLSWOR-UHFFFAOYSA-M
0.000
description
1
125000001624
naphthyl group
Chemical group
0.000
description
1
210000002682
neurofibrillary tangle
Anatomy
0.000
description
1
231100000189
neurotoxic
Toxicity
0.000
description
1
230000002887
neurotoxic effect
Effects
0.000
description
1
238000011587
new zealand white rabbit
Methods
0.000
description
1
235000008935
nutritious
Nutrition
0.000
description
1
QIQXTHQIDYTFRH-UHFFFAOYSA-N
octadecanoic acid
Chemical compound
CCCCCCCCCCCCCCCCCC(O)=O
QIQXTHQIDYTFRH-UHFFFAOYSA-N
0.000
description
1
OQCDKBAXFALNLD-UHFFFAOYSA-N
octadecanoic acid
Natural products
CCCCCCCC(C)CCCCCCCCC(O)=O
OQCDKBAXFALNLD-UHFFFAOYSA-N
0.000
description
1
239000003921
oil
Substances
0.000
description
1
235000019198
oils
Nutrition
0.000
description
1
239000002674
ointment
Substances
0.000
description
1
238000003305
oral gavage
Methods
0.000
description
1
239000002245
particle
Substances
0.000
description
1
239000006072
paste
Substances
0.000
description
1
230000001717
pathogenic effect
Effects
0.000
description
1
230000035515
penetration
Effects
0.000
description
1
125000001147
pentyl group
Chemical group
C(CCCC)*
0.000
description
1
235000019477
peppermint oil
Nutrition
0.000
description
1
229940098804
peridex
Drugs
0.000
description
1
230000035699
permeability
Effects
0.000
description
1
239000000049
pigment
Substances
0.000
description
1
229960003890
pimagedine
Drugs
0.000
description
1
239000004033
plastic
Substances
0.000
description
1
229920003023
plastic
Polymers
0.000
description
1
238000007747
plating
Methods
0.000
description
1
229940068918
polyethylene glycol 400
Drugs
0.000
description
1
229920001184
polypeptide
Polymers
0.000
description
1
230000003334
potential effect
Effects
0.000
description
1
239000003755
preservative agent
Substances
0.000
description
1
102000004196
processed proteins & peptides
Human genes
0.000
description
1
230000000750
progressive effect
Effects
0.000
description
1
230000002035
prolonged effect
Effects
0.000
description
1
125000001436
propyl group
Chemical group
[H]C([*])([H])C([H])([H])C([H])([H])[H]
0.000
description
1
238000010926
purge
Methods
0.000
description
1
238000011552
rat model
Methods
0.000
description
1
239000000376
reactant
Substances
0.000
description
1
230000000979
retarding effect
Effects
0.000
description
1
238000003118
sandwich ELISA
Methods
0.000
description
1
238000007789
sealing
Methods
0.000
description
1
230000003248
secreting effect
Effects
0.000
description
1
230000035945
sensitivity
Effects
0.000
description
1
238000001542
size-exclusion chromatography
Methods
0.000
description
1
229910052708
sodium
Inorganic materials
0.000
description
1
239000011780
sodium chloride
Substances
0.000
description
1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M
sodium dihydrogen phosphate
Chemical compound
[Na+].OP(O)([O-])=O
AJPJDKMHJJGVTQ-UHFFFAOYSA-M
0.000
description
1
239000007909
solid dosage form
Substances
0.000
description
1
239000000600
sorbitol
Substances
0.000
description
1
230000003595
spectral effect
Effects
0.000
description
1
210000004988
splenocyte
Anatomy
0.000
description
1
230000000087
stabilizing effect
Effects
0.000
description
1
238000010561
standard procedure
Methods
0.000
description
1
239000008117
stearic acid
Substances
0.000
description
1
238000003756
stirring
Methods
0.000
description
1
238000007920
subcutaneous administration
Methods
0.000
description
1
125000001424
substituent group
Chemical group
0.000
description
1
239000000725
suspension
Substances
0.000
description
1
238000010189
synthetic method
Methods
0.000
description
1
239000006188
syrup
Substances
0.000
description
1
235000020357
syrup
Nutrition
0.000
description
1
239000003826
tablet
Substances
0.000
description
1
LMBFAGIMSUYTBN-MPZNNTNKSA-N
teixobactin
Chemical compound
C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1
LMBFAGIMSUYTBN-MPZNNTNKSA-N
0.000
description
1
150000003557
thiazoles
Chemical class
0.000
description
1
125000003396
thiol group
Chemical group
[H]S*
0.000
description
1
229960002175
thyroglobulin
Drugs
0.000
description
1
125000003944
tolyl group
Chemical group
0.000
description
1
229940034610
toothpaste
Drugs
0.000
description
1
231100000419
toxicity
Toxicity
0.000
description
1
230000001988
toxicity
Effects
0.000
description
1
235000013311
vegetables
Nutrition
0.000
description
1
239000003981
vehicle
Substances
0.000
description
1
239000011534
wash buffer
Substances
0.000
description
1
230000003442
weekly effect
Effects
0.000
description
1
238000005550
wet granulation
Methods
0.000
description
1
239000012224
working solution
Substances
0.000
description
1
125000005023
xylyl group
Chemical group
0.000
description
1
Classifications
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/425—Thiazoles
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/425—Thiazoles
A61K31/426—1,3-Thiazoles
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/425—Thiazoles
A61K31/428—Thiazoles condensed with carbocyclic rings
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K8/00—Cosmetics or similar toiletry preparations
A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P13/00—Drugs for disorders of the urinary system
A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P15/00—Drugs for genital or sexual disorders; Contraceptives
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P19/00—Drugs for skeletal disorders
A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P27/00—Drugs for disorders of the senses
A61P27/02—Ophthalmic agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P3/00—Drugs for disorders of the metabolism
A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P3/00—Drugs for disorders of the metabolism
A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P7/00—Drugs for disorders of the blood or the extracellular fluid
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
A61Q19/00—Preparations for care of the skin
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
A61Q19/00—Preparations for care of the skin
A61Q19/08—Anti-ageing preparations
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D277/38—Nitrogen atoms
C07D277/40—Unsubstituted amino or imino radicals
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N33/6854—Immunoglobulins
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N2500/00—Screening for compounds of potential therapeutic value
G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Description
WO 96/22095 PCTI/US96/00663 USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION END PRODUCTS BACKGROUND OF THE INVENTION The present invention relates generally to the aging of proteins resulting from their reaction with glucose and other reducing sugars, and more particularly to the inhibition of the reaction of nonenzymatically glycosylated proteins and the breaking of crosslinked formed subsequent to formation of advanced glycosylation (glycation) endproducts.
The reaction between glucose and proteins has been known for some time. Its earliest manifestation was in the appearance of brown pigments during the cooking of food, which was identified by Maillard in 1912, who observed that glucose or other reducing sugars react with amino acids to form adducts that undergo a series of dehydrations and rearrangements to form stable brown pigments. Further studies have suggested that stored and heat treated foods undergo nonenzymatic browning as a result of the reaction between glucose and the polypeptide chain, and that the proteins are resultingly crosslinked and correspondingly exhibit decreased bioavailability.
This reaction between reducing sugars and food proteins was found to have its parallel in vivo. Thus, the nonenzymatic reaction between glucose and the free amino groups on proteins to form a stable, 1-deoxyketosyl adduct, known as the Amadori product, has been shown to occur with hemoglobin, wherein a rearrangement of the amino terminal of the beta-chain of hemoglobin by reaction with glucose, forms the adduct known as hemoglobin Alc. The reaction has also been found to occur with a variety of other body proteins, such as lens crystallins, collagen and nerve proteins. See Bucala et al., «Advanced Glycosylation; Chemistry, Biology, and Implications for Diabetes and Aging» in Advances in Pharmacology, Vol. 23, pp. 1-34, Academic Press (1992).
Moreover, brown pigments with spectral and fluorescent properties similar to those of late-stage Maillard products have also been observed in vivo in association with several long-lived proteins, such as lens proteins and collagen from aged individuals. An agerelated linear increase in pigment was observed in human dura collagen between the ages of 20 to 90 years. Interestingly, the aging of collagen can be mimicked in vitro by SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 2 the cross-linking induced by glucose; and the capture of other proteins and the formation of adducts by collagen, also noted, is theorized to occur by a cross-linking reaction, and is believed to account for the observed accumulation of albumin and antibodies in kidney basement membrane.
In U.S. Patent 4,758,583, a method and associated agents were disclosed that served to inhibit the formation of advanced glycosylation endproducts by reacting with an early glycosylation product that results from the original reaction between the target protein and glucose. Accordingly, inhibition was postulated to take place as the reaction between the inhibitor and the early glycosylation product appeared to interrupt the subsequent reaction of the glycosylated protein with additional protein material to form the cross-linked late-stage product. One of the agents identified as an inhibitor was aminoguanidine, and the results of further testing have borne out its efficacy in this regard.
While the success that has been achieved with aminoguanidine and similar compounds is promising, a need continues to exist to identify and develop additional inhibitors that broaden the availability and perhaps the scope of this potential activity and its diagnostic and therapeutic utility. A further need exists to find agents which not only inhibit this reaction and its consequences, but agents capable of breaking the cross-links formed as a result of pre-existing advanced glycosylation endproducts, thereby reversing the resultant effects thereof.
SUMMARY OF THE INVENTION In accordance with the present invention, a method and compositions are disclosed for the inhibition of formation of advanced glycosylation of proteins (protein aging) and for breaking the cross-links that form between advanced glycosylation (glycation) endproducts (AGEs) or between AGEs and other proteins. Advanced glycosylation (glycation) endproducts and cross-linking caused by other reactive sugars present in vivo or in foodstuffs, including ribose, galactose and fructose would also be prevented and reversed by the methods and compositions of the present invention.
SUBSTITUTE SHEET (RULE 26) In particular, the compositions comprise agents for inhibiting the formation of and reversing the pre-formed advanced glycosylation (glycation) endproducts and breaking the subsequent cross-links. While not wishing to be bound by any theory, it is believed that the breaking of the pre-formed advanced glycosylation (glycation) endproducts and cross-links is a result of the cleavage of a dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. The methods and compositions of this invention are thus directed to agents which, by their ability to effect such cleavage, can be utilized to break the pre-formed advanced glycosylation endproduct and cross-link, and the resultant deleterious effects thereof, both in vitro and in vivo.
S Certain of the agents useful in this present invention are members of the class of compounds known as thiazoliums.
o The agents comprise one or more compounds selected from thiazolium compounds having the following structural formula: Y X
I
RI N- R S (I) 0 Swherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower S*.2 alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 0 O 11 I-CH 2
C-R
1 wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which Saryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, 4 di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R is aryl, at least one of R 1 and R 2 is other than hydrogen and R 1 and R 2 are not part of an unsubstituted fused phenyl ring; a group of the formula -CH2R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula O R» 1I I
-CH
2
C-N-R»‘
wherein R» is hydrogen and is a lower alkyl group, which alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be l substituted by one or more lower alkyl, halo, or lower alkoxycarbonyl groups; or (ii) R» and are both lower alkyl groups; and SX is a pharmaceutically acceptable anion, such as a halide, tosylate, methanesulfonate or mesitylenesulfonate ion; and a carrier therefor.
The compounds, and their compositions, utilized in this invention appear to react with an early glycosylation product thereby preventing the same from later forming S the advanced glycosylation end products which lead to cross-links, and thereby, to molecular or protein aging and other adverse molecular consequences. Additionally, they react with already formed advanced glycosylation end products to reduce the S* amount of such products.
The present invention also relates to a method for inhibiting protein aging and other adverse molecular consequences by contacting the initially glycosylated molecules at the stage of the early glycosylation product with a quantity of one or more of the agents of the present invention, or a composition containing the same, and to a RZ4thod for breaking the already formed advanced glycosylation end products to reduce the amount of such products by cleaving the a-dicarbonyl-based crosslinks present in the advanced glycosylation endproducts. In the instance where the present method has industrial application, one or more of the agents may be applied to the proteins in question, for instance, either by introduction into a mixture of the same in the instance of a protein extract, or by application or introduction into foodstuffs susceptible to advanced glycation and crosslinking, all to prevent premature aging and spoilage of the particular foodstuffs, and to reverse the effects of already formed advanced glycosylation end products.
The ability to inhibit the formation of advanced glycosylation endproducts, and to 0: reverse the already formed advanced glycosylation products in the body carries with it significant implications in all applications where advanced glycation and S concomitant molecular crosslinking is a serious detriment. Thus, in the area of food :1i~ technology, for instance, the retardation of food spoilage would confer an obvious S economic and social benefit by making certain foods of marginal stability less perishable and therefore more available for consumers. Spoilage would be reduced as would the expense of inspection, removal, and replacement, and the extended availability of the foods could aid in stabilizing their price in the marketplace.
Q Similarly, in other industrial applications where the perishability of proteins is a problem, the admixture of the agents of the present invention in compositions S containing such proteins would facilitate the extended useful life of the same.
S Presently used food preservatives and discoloration preventatives such as sulfur dioxide, known to cause toxicity including allergy and asthma in animals, can be replaced with compounds such as those described herein.
•0 00 The present method has particular therapeutic application as the Maillard process acutely affects several of the significant protein masses in the body, among them collagen, elastin, lens proteins, and the kidney glomerular basement membranes.
These proteins deteriorate both with age (hence the application of the term «protein and as a consequence of diabetes. Accordingly, the ability to either retard or 6 substantially inhibit the formation of advanced glycosylation endproducts, and to reduce the amount of cross-links formed between advanced glycosylation endproducts and other proteins in the body carries the promise for treatment of the complications of diabetes and aging for instance, and thereby improving the quality and, perhaps, duration of animal and human life. For example, the compounds of the present invention can be used to improve the elasticity or reduce wrinkles of the skin, treat diabetes, or treat or prevent adverse sequelae of diabetes, kidney damage, damage to blood vasculature, hypertension, retinopathy, damage to lens proteins, cataracts, peripheral neuropathy or osteoarthritis.
The present agents are also useful in the area of personal appearance and hygiene, as S they prevent, and reverse, the staining of teeth by cationic anti-microbial agents with anti-plaque properties, such as chlorhexidine.
I
The invention additionally comprises a novel analytic method for the determination of the «breaking» or reversal of the formation of non-enzymatic endproducts. In this connection, the invention further extends to the identification and use of a novel cross-link structure which is believed to represent a significant number of the 20 molecular crosslinks that form in vitro and in vivo as a consequence of advanced glycation. More particularly, the cross-link structure includes a sugar-derived adicarbonyl segment or moiety, such as a diketone, that is capable of cleavage by a dinucleophilic, thiazolium-like compound. Specifically, the cross-link structure may be according to the formula: .2
O
OA 0 where A and B, independently, are sites of attachment to the nucleophilic atom of a biomolecule.
7 Accordingly, it is a principal object of the present invention to provide a method for inhibiting the formation of advanced glycosylation endproducts and extensive crosslinking of molecules, and a method of breaking the cross-links formed from preexisting advanced glycosylation endproducts, that occur as a consequence of the reaction of susceptible molecules such as proteins with glucose and other reactive sugars, by correspondingly inhibiting the formation of advanced glycosylation endproducts, and breaking the advanced glycosylation mediated cross-linking that has previously occurred.
It is a further object of the present invention to provide a method as aforesaid which is characterized by a reaction with an initially glycosylated protein identified as an 0 early glycosylation product.
S’1. It is a further object of the present invention to provide a method as aforesaid which prevents the rearrangement and cross-linking of the said early glycosylation S products to form the said advanced glycosylation endproducts.
It is a further object of the present invention to provide a method for treating 2 foodstuffs containing protein material so as to inhibit the undesired molecular t. S changes therein caused by the formation of advanced glycosylation endproducts of a target protein within the foodstuff. This method comprises treating the foodstuff o* with an effective amount of a dinucleophilic thiazolium compound capable of reacting with a sugar-derived, non-enzymatically formed cross-link structure, found 25 both in vitro and in vivo, which includes an a-dicarbonyl moiety, and in particular the cross-link structure shown above.
It is a yet further object of the present invention to provide agents capable of participating in the reaction with the said early glycosylation products in the method as aforesaid.
7a It is a yet further object of the present invention to provide agents which break or reverse the advanced glycosylation endproducts formed as a consequence of the aforesaid advanced glycosylation reaction sequence by cleaving the a-dicarbonylbased protein crosslinks present in the advanced glycosylation endproducts.
Suitable agents are thiazolium compounds which are substituted on the ring nitrogen with an amino group or a hydrogen substituted methylene group which is alpha to a carbonyl, ethynyl or (C6-C10) aryl group, wherein the aryl group can be substituted with one or more lower alkyl, lower alkoxy, halo, di(lower alkyl) amino, hydroxy, nitro or alkylenedioxy groups; and substituted at the 2-position of the thiazolium ring with hydrogen or amino; and wherein the thiazolium compound is reactive to S break pre-formed, non-enzymatic glycosylation crosslinks. More specifically, the S: thiazolium compound may be substituted on the ring nitrogen with a hydrogen Y substituted methylene group which is alpha to a carbonyl or ethynyl group, and S substituted at the 2-position of the ring with hydrogen; the thiazolium compound may be substituted on the ring nitrogen with an amino group or a hydrogen substituted methylene group which is alpha to a carbonyl group, and substituted at the 2-position of the ring with hydrogen or amino; or the thiazolium compound 2) may be substituted on the ring nitrogen with a hydrogen substituted methylene group which is alpha to a carbonyl group, and substituted at the 2-position of the ring with hydrogen.
0 It is still a further object of the present invention to provide therapeutic methods of S* 2 treating the adverse consequences of molecular or protein aging by resort to the aforesaid method and agents.
It is a still further object of the present invention to provide a method of inhibiting, and reversing, the discoloration of teeth by resort to the aforesaid method and agents. It is a still further object of the present invention to provide compositions, ping pharmaceutical compositions, all incorporating the agents of the present It is a still further object of the present invention to provide novel compounds, as well as processes for their preparations, for use in the methods and compositions of the present invention.
It is a still further object of the present invention to provide novel assays which can be utilized to detect compounds having the ability to «break» or reverse the formation of non-enzymatic glycosylation endproducts and their subsequent crosslinks.
It is a yet further object of the present invention to provide a cross-link structure that is capable of cleavage by the agents that break or reverse the formation of advanced glycosylation endproducts as set forth herein, and the antibodies specific to said cross-link structure, and the diagnostic and therapeutic uses thereof.
Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing description which proceeds with reference to the following illustrative drawings.
0.20 BRIEF DESCRIPTION OF THE DRAWING FIGURES S FIGURE 1 is an SDS-PAGE gel showing the CNBrr Peptide Maps of Tail Tendon Collagen from Normal and diabetic rates following incubation with 3-(2-phenyl-2oxoethyl)thiazolium bromide (designated as ALT-766) of the present invention.
OS
WO 96/22095 PCT/US96/00663 8 FIGURE 2 is an SDS-PAGE gel showing the physical evidence for the breaking of cross-linked AGE-BSA by 3-(2-phenyl-2-oxoethyl)thiazolium bromide, a compound of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS In accordance with the present invention, agents, compositions including pharmaceutical compositions containing said agents and associated methods have been developed which are believed to inhibit the formation of advanced glycosylation endproducts in a number of target molecules, including particularly proteins, existing in both animals and plant material, and to reverse the already formed advanced glycosylation endproducts. In particular, the invention relates to a composition which may contain one or more agents comprising compounds having the ability to effect cleavage of a-dicarbonyl-based molecular crosslinks present in the advanced glycosylation endproducts. Useful agents, for instance, comprise compounds having the structural formula: Y X R S wherein RI and R2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, acetoxy(lower)alkyl, lower alkyl, lower alkenyl, or RI and R2 together with their ring carbons may be an aromatic fused ring, optionally substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula
O
II
-CH
2
C-R
wherein R is a lower alkyl, alkoxy, hydroxy, amino or an aryl group, said aryl group optionally substituted by one or more lower alkyl, lower alkoxy, halo, dialkylamino, hydroxy, nitro or alkylenedioxy groups; a group of the formula SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 9
-CH
2
R’
wherein R’ is hydrogen, or a lower alkyl, lower alkynyl, or aryl group; or a group of the formula O R» II I
-CH
2
C-N-R»‘
wherein R» is hydrogen and is a lower alkyl group, optionally substituted by an aryl group, or an aryl group, said aryl group optionally substituted by one or more lower alkyl, halo, or alkoxylcarbonyl groups; or R» and are both lower alkyl groups; X is a halide, tosylate, methanesulfonate or mesitylenesulfonate ion; and mixtures thereof, and a carrier therefor.
The lower alkyl groups referred to above contain 1-6 carbon atoms and include methyl, ethyl, propyl, butyl, pentyl, hexyl, and the corresponding branched-chain isomers thereof. The lower alkynyl groups contain from 2 to 6 carbon atoms. Similarly, the lower alkoxy groups contain from 1 to 6 carbon atoms, and include methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexoxy, and the corresponding branched-chain isomers thereof. These groups are optionally substituted by one or more halo, hydroxy, amino or lower alkylamino groups.
The lower acyloxy(lower)alkyl groups encompassed by the above formula include those wherein the acyloxy portion contain from 2 to 6 carbon atoms and the lower alkyl portion contains from 1 to 6 carbon atoms. Typical acyloxy portions are those such as acetoxy or ethanoyloxy, propanoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy, and the corresponding branched chain isomers thereof. Typical lower alkyl portions are as described hereinabove.
The aryl groups encompassed by the above formula are those containing 6-10 carbon atoms, such as naphthyl, phenyl and lower alkyl substituted-phenyl, tolyl and xylyl, and are optionally substituted by 1-2 halo, hydroxy, lower alkoxy or di(lower)alkylamino groups. Preferred aryl groups are phenyl, methoxyphenyl and 4bromophenyl groups.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 WO 9622095PCTIUS96/00663 The halo atoms in the above formula may be fluoro, chioro, bromo or iodo.
For the purposes of this invention, the compounds of formnula are formed as biologically and pharmaceutically acceptable salts. Useful salt forms are the halides, particularly the bromide and chloride, tosylate, methanesulfonate, and mesitylenesulfonate salts. Other related salts can be formed using similarly non-toxic., and biologically and pharmaceutically acceptable anions.
Of the compounds encompassed by Formula I, certain substituents are preferred. For instance, the compounds wherein RI or R, 2 are lower alkyl groups are preferred. Also highly preferred are the compounds wherein Y is an amino group, a 2-amino-2oxoethyl group, a 2-phenyl-2-oxoethyl or a 2-[substituted phenyl]-2-oxoethyl group.
Representative compounds of the present invention are: 3-aminothiazolium mesitylenesulfonate; 3-amino-4,5-dimethylaminothiazolium mesitylenesulfonate; 2,3-diaminothiazolinium mesitylenesulfonate; 3-(2-methoxy-2-oxoethyl)-thiazolium bromide; 3 2 -methoxy-2-oxoethyl)-4,5-dimethylthiazolium bromide; 3 2 -methoxy-2-oxoethyl)-4-methylthiazolium bromide; 3-(2-phenyl-2-oxoethyl)-4-methylthiazolium bromide; 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide; 3-amino-4-methylthiazolium mesitylenesulfonate; 3-(2-methoxy-2-oxoethyl)-5-methylthiazolium bromide; 3 3 2 -phenyl-2-oxoethyl)-5-methylthiazolium bromide; -bromophenyl )-2-oxoethyl]thiazolium bromide; -bromophenyl)-2-oxoethyl]-4-methylthiazolium bromide; -bromophenyl)-2-oxoethyl]-5-methylthiazolium bromide; bromophenyl)-2-oxoethyll-4,5-dimethylthiazolium bromide; 3 2 -methoxy-2-oxoethyl)-4-methyl-5-(2-hydroxyethyl)thiazolium bromide; 3 -(2-phenyl-2-oxoethyl)-4-methyl-5-(2-hydroxyetiyl)thiazolium bromide; 3-[2-(4′-boohnl -xehl–ehy.5(-yrxehltizlu bromide; 3,4-dimethyl-5-(2-hydroxyethyl)thiazolium iodide; SUBSTITUTE SHEET (RULE 26) WO 96/22095 PTU9/06 PCTIUS96/00663 1 1 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide; 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride; 3-(2-methoxy-2-oxoethyl)benzothiazolium bromide; 3-(2-phenyl-2-oxoethyl)benzothiazolium bromide; bromophenyl)-2-oxoethyllbenzothiazolium bromide; 3-(carboxymethyl)benzothiazolium bromide; 2,3-(diamino)benzothiazolium mesitylenesulfonate; 3-(2-amino-2-oxoethyl)thiazolium bromide; 3-(2-amino-2-oxoethyl)-4-methylthiazolium bromide: 3-(2-amino-2-oxoethyl)-5-methylthiazolium bromide; 3-(2-amino-2-oxoethyl)4,5-dimethylthiazolium bromide; 3-(2-amino-2-oxoethyl)benzothiazolium bromide; 3-(2-amino-2-oxoethyl)4-methyl-5-(2-hydroxyethyl)thiazolium bromide; 3-amino-5-(2-hydroxyethyl)-4-methylthiazolium mesitylenesulfonate; 3-(2-methyl-2-oxoethyl)thiazolium chloride; 3-amino-4-methyl-5-(2-acetoxyethyl)thiazolium mesitylenesulfonate; 3-(2-phenyl-2-oxoethyl)thiazolium bromide; 3-(2-methoxy-2-oxoethyl)-4-methyl-5-(2-acetoxyethyl)thiazolium bromide; 3-(2-amino-2-oxoethyl)-4-methyl-5-(2-acetoxyethyl)thiazolium bromide; 2-amino-3-(2-methoxy-2-oxoethyl)thiazolium bromide; 2-amino-3-(2-methoxy-2-oxoethyl)benzothiazolium bromide; 2-amino-3-(2-amino-2-oxoethyl)thiazolium bromide; 2-amino-3-(2-am-ino-2-oxoethyl)benzothiazolium bromide; -methoxyphenyl)-2-oxoethyl]-thiazolinium bromide; 3- -dimethoxyphenyl)-2-oxoethyl]-thiazolinium bromide; -fluorophenyl)-2-oxoethyl]-thiazolinium bromide; 3- -difluorophenyl)-2-oxoethyl]-thiazolinium bromide; 3-[2-(4′-diethylaminophenyl)-2-oxoethyll-thiazolinium bromide; 3-propargyl-thiazolinium bromide; SUBSTITUTE SHEET (RULE 26) WO 96/22095 PTU9106 PCTIUS96/00663 12 3-propargyl-4-methylthiazolinium bromide; bromide; 3-propargyl-4,5-dimethylthiazolinium bromide; 3-propargyl-4-methyl-5-(2-hydroxyethyl)-thiazolinium bromide; 3-(2-13′-methoxyphenyl]-2-oxoethyl)-thiazolium bromide; 3-(2-[3′-methoxy phenyl]-2-oxoethyl)-4 methyl-5-(2′-hydroxyethyl)-thiazolium bromide; 3-(2-[3′-methoxyphenyl]-2-oxoethyl)-benzothiazolium bromide; 2,3-diamino-4-chlorobenzothiazolium mesitylenesulfonate; 2,3-diamino-4-methyl-thiazolium mesitylenesulfonate; 3-amino-4-methyl-5-vinyl-thiazolium mesitylene-sulfonate; 2,3-diamino-6-chlorobenzothiazolium mesitylenesulfonate; 2,6-diamino-benzothiazole dihydrochioride; 2,6-diamino-3 [2-(4′-methoxyphenyl)-2-oxoethyl] benzothiazoliumn bromide; 2,6-diarnino-3 [2-(3′-methoxyphenyl)-2-oxoethyl] benzothiazoliumn bromide; 2,6-diamino-3 [2-(4′-diethylaminophenyl)-2-oxoethyl] benzothiazolium bromide; 2,6-diamino-3(2-(4′-bromophenyl)-2-oxoethyll benzothiazoliumn bromide; 2,6-diamino-3(2-(2-phenyl-2-oxoethyl) benzothiazoliumn bromide; 2,6-diamino-3 [2-(4′-fluorophenyl-2-oxoethyl] benzothiazoliumn bromide; 3-acetanmido-4-methyl-5-thiazolyl-ethyl acetate mesitylenesulfonate; 2,3-diamino-5-methylthiazolium mesitylenesulfonate; 3-[2-(2′-naphthyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; 3-[2-(3′,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-4-methyl-5- (2’hydroxyethyl)thiazoliumn bromide; 3-[2-(2′,6′-dichlorophenethylamino)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)thiazolium-bromide; 3-[2-dibutylamino-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; [2-4′-carbethoxyanilino)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; 3-[2-(2′,6′-diisopropylanilino)-2-oxoethyll-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; 3-amino-4-methyl-5-[2-(2′,6′-dichlorobenzyloxy)ethyll-thioazolium mesitylenesulfonate; SUBSTITUTE SHEET (RULE 26) WO 96/22095 PTU9106 PCTIUS96/00663 13 3-[2-(4′-carbmethoxy-3′-hydroxyanilino)-2-oxoethylII-4-methyl-5-(2′-hydroxyethyl)thiazolium bromide; 2,3-diamino-4,5-dimethylthiazolium mesitylene sulfonate:, 2,3-diamino-4-methyl-5-hydroxyethyl-thiazolium mesitylene sulfonate; 2,3-diamino-5-(3′,4′-trimethylenedioxy phenyl)-thiazolium mesitylene sulfonate; 3 -benzodioxan-6-yl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; 3-[2-(3′,4′-trimethylenedioxyphenyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)thiazolium bromide; 1′,4-benzodioxan-6-yl]-2-oxoethyl)-thiazolium bromide; 3-[2-(3′,4′-trimethylenedioxyphenyl)-2-oxoethyl]-thiazolium bromide; 3-[2-(3′,5′-di-tert-buty I-4′-hydroxyphenyl)-2-oxoethyl]-thiazolium bromide; 3-[2-(3′,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-4-methyl-thiazolium bromide; 3-[2-(3 t ,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-5-methyl-thiazolium bromide; 3-[2-(3′,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-thiazolium bromide; 3- [2-(3′,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl ]-benzothiazolium bromide; 1 -methyl-3- ,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-imidazolium bromide; 3-[2-(4′-n-pentylphenyl)-2-oxoethylll-thiazolinium bromide; 3-[2-(4′-n-pentylphenyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolinium bromide; 3-[2-4 t -diethylaminophenyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolinium bromide; 3-(2-phenyl-2-oxoethyl )-4-methyl-5-vinyl-thiazolium bromide; t -tert-butyl-4′-hydroxyphenyl)-2-oxoethyl)-4-methyl-5-vinyl-thiazolium bromide; 3-(2-tert-butyl-2-oxoethyl)-thiazolium bromide 3-(2-tert-butyl-2-oxoethyl)-4-methyl-5- (2′-hydroxyethyl)-thiazolium bromide; 3-(3′-methoxybenzyl)-4-methyl-5-(2′-hydroxyethyl)-thiazolium chloride; 3-(2′,6′-dichlorobenzyl)-4-methyl-5-(2′-hydroxyethyl)-thiazolium chloride; 3-(2′-nitrobenzyl)-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; 3[2-(4′-chlorophenyl)-2-oxoethyl]-thiazolium b romide; SUBSTITUTE SHEET (RULE 26) 14 3[2-(4′-chlorophenyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide; and 3[2-(4′-methoxyphenyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl)-thiazolium bromide.
Certain of the compounds represented by Formula I are novel compounds which represent a further embodiment of the present invention. These compounds are represented by the formula Y X Rj N R (Ia) wherein: .7 Y and Z are both amino groups and R 1 and R 2 are independently selected from the group consisting of hydroxy(lower)alkyl, lower acyloxy(lower)alkyl and lower alkyl, or one of R 1 or R 2 is hydrogen, or R 1 or R 2 together with their ring carbons form an aromatic fused ring substituted by one or more amino, halo or alkylenedioxy groups; or S0 (ii) R 1
R
2 and Z are hydrogen; and Y is a group of the formula -CH 2 C(=O)R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, with the proviso that Y is not 2-phenyl-2- 25 oxoethyl or 2-(3′-methoxypheny)-2-oxoethyl; a group of the formula
-CH
2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula -CH 2 wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or alkoxycarbonyl groups; or R» and are both lower alkyl groups; or (iii) R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; and Y is an alkynylmethyl group or a group of the formula
-CH
2 C(=O)NHR wherein R is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or alkoxycarbonyl groups; or (iv) R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and S lower alkenyl, with the provisos that R 1 and R 2 cannot both be hydrogen and
R
1 and R 2 cannot both be methyl, and with the further proviso that, when R 2 is hydrogen, R 1 is other than methyl; or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen; and •.20 Y is amino; or S R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl; or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or 25 alkylenedioxy groups; Z is an amino group; and Y is a group of the formula -CH 2 C(=O)R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl) amino, hydroxy, nitro or alkylenedioxy groups; or a group of the formula
-CH
2 R’ wherein R’ is hydrogen or a lower alkyl or aryl group; s <4Id X is a pharmaceutically acceptable anion.
The above compounds are capable of inhibiting the formation of advanced glycosylation endproducts on target molecules, including, for instance, proteins, as well as being capable of breaking or reversing already formed advanced glycosylation endproducts on such proteins. The cross-linking of protein by formation of advanced glycosylation endproducts contributes to the entrapment of other proteins and results in the development in vivo of conditions such as reduced elasticity and wrinkling of the skin, certain kidney diseases, atherosclerosis, osteoarthritis and the like. Similarly, plant material that undergoes nonenzymatic browning deteriorates and, in the case of foodstuffs, become spoiled or toughened and, consequently, inedible, unpalatable or non-nutritious. Thus, the compounds employed in accordance with this invention
OO*
0*
S
SS
WO 96/22095 PCTIS96/00663 16 inhibit this late-stage Maillard effect and intervene in the deleterious changes described above, and reduce the level of the advanced glycosylation endproducts already present in the protein material.
The rationale of the present invention is to use agents which block, as well as reverse, the post-glycosylation step, the formation of fluorescent chromophores and crosslinks, the presence of which is associated with, and leads to adverse sequelae of diabetes and aging. An ideal agent would prevent the formation of such chromophores and of cross-links between protein strands and trapping of proteins onto other proteins, such as occurs in arteries and in the kidney, and reverse the level of such cross-link formation already present.
The chemical nature of the early glycosylation products with which the compounds of the present invention are believed to react may vary, and accordingly the term "early glycosylation product(s)" as used herein is intended to include any and all such variations within its scope. For example, early glycosylation products with carbonyl moieties that are involved in the formation of advanced glycosylation endproducts, and that may be blocked by reaction with the compounds of the present invention, have been postulated. In one embodiment, it is envisioned that the early glycosylation product may comprise the reactive carbonyl moieties of Amadori products or their further condensation, dehydration and/or rearrangement products, which may condense to form advanced glycosylation endproducts. In another scenario, reactive carbonyl compounds, containing one or more carbonyl moieties (such as glycolaldehyde, glyceraldehyde or 3-deoxyglucosone) may form from the cleavage of Amadori or other early glycosylation endproducts, and by subsequent reactions with an amine or Amadori product, may form carbonyl containing advanced glycosylation products such as alkylformyl-glycosylpyrroles.
Several investigators have studied the mechanism of advanced glycosylation product formation. In vitro studies by Eble et al., (1983), "Nonenzymatic Glucosylation and Glucose-dependent Cross-linking of Protein", J. Biol. Chem., 258:9406-9412, concerned the cross-linking of glycosylated protein with nonglycosylated protein in the absence of glucose. Eble et al. sought to elucidate the mechanism of the Maillard SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 17 reaction and accordingly conducted controlled initial glycosylation of RNase as a model system, which was then examined under varying conditions. In one aspect, the glycosylated protein material was isolated and placed in a glucose-free environment and thereby observed to determine the extent of cross-linking.
Eble et al. thereby observed that cross-linking continued to occur not only with the glycosylated protein but with non-glycosylated proteins as well. One of the observations noted by Eble et al. was that the reaction between glycosylated protein and the protein material appeared to occur at the location on the amino acid side-chain of the protein. Confirmatory experimentation conducted by Eble et al. in this connection demonstrated that free lysine would compete with the lysine on RNase for the binding of glycosylated protein. Thus, it might be inferred from these data that lysine may serve as an inhibitor of advanced glycosylation; however, this conclusion and the underlying observations leading to it should be taken in the relatively limited context of the model system prepared and examined by Eble et al. Clearly, Eble et al. does not appreciate, nor is there a suggestion therein, of the discoveries that underlie the present invention, with respect to the inhibition of advanced glycosylation of proteins both in vitro and in vivo.
The experiments of Eble et al. do not suggest the reactive cleavage product mechanism or any other mechanism in the in vivo formation of advanced glycosylation endproducts in which glucose is always present. In fact, other investigators support this mechanism to explain the formation of advanced glycosylated endproducts in vivo (see for example, Hayase et al, J. Biol. Chem., 263:3758-3764 (1989); Sell and Monnier, J. Biol. Chem., 264:21597-21602 (1989); Oimomi et al., Agric. Biol. Chem., 53(6):1727-1728 (1989); and Diabetes Research and Clinical Practice, 6:311-313 (1989). Accordingly, the use of lysine as an inhibitor in the Eble et al. model system has no bearing upon the utility of the compounds of the present invention in the inhibition of advanced glycosylated endproducts formation in the presence of glucose in vivo, and the amelioration of complications of diabetes and aging.
While not wishing to be bound by any particular theory as to the mechanism by which the compounds of the instant invention reverse already formed advanced glycosylation endproducts, studies have been structured to elucidate a possible mechanism. Earlier SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 18 studies examining the fate of the Amadori product (AP) in vivo have identified one likely route that could lead to the formation of covalent, glucose-derived protein crosslinks. This pathway proceeds by dehydration of the AP via successive betaeliminations as shown in the Scheme A below. Thus, loss of the 4-hydroxyl of the AP gives a 1,4-dideoxy-l-alkylamino-2,3-hexodiulose (AP-dione) An AP-dione with the structure of an amino- 1,4-dideoxyosone has been isolated by trapping model APs with the AGE-inhibitor aminoguanidine. Subsequent elimination of the hydroxyl gives a 1,4,5-trideoxy-1-alkylamino-2,3-hexulos-4-ene (AP-ene-dione) which has been isolated as a triacetyl derivative of its 1,2-enol form. Amadori-diones, particularly the AP-ene-dione, would be expected to be highly reactive toward protein crosslinking reactions by serving as targets for the addition of the amine (Lys, His)-, or sulfhydryl (Cys)-based nucleophiles that exist in proteins, thereby producing stable crosslinks of the form N Lys] H-Lysl H H 0 HN Lys] N-(Lyus X{Protein] H OOH OH
-H
2 0 -H20 X- Protein] 1 OH OH OH*OH H X-[Protein] H on o o I II III IV Note that the linear AP-ene-dione of and the stable cross-link of may cyclize to form either 5- or 6-member lactol rings, although only the 6-member cyclic variant is shown in Scheme A set forth above.
The possibility that a major pathway of glucose-derived crosslink formation proceeds through an AP-ene-dione intermediate was investigated by experiments designed to test the occurrence of this pathway in vivo as well as to effect the specific cleavage of the resultant a(-dicarbonyl-based protein crosslinks. The thiazolium compounds of the instant invention are thus believed to act as novel "bidentate" nucleophiles, particularly designed to effect a carbon-carbon breaking reaction between the two carbonyls of the crosslink, as shown in Scheme B below under physiological conditions. This scheme SUBSTITUTE SHEET (RULE 26) I -1 WO 96/22095 PCT/US96/00663 19 shows the reaction of a prototypic a-dione cleaving agent of the formula I, Nphenacylthiazolium bromide, with an AP-ene-dione derived crosslink.
[LysrN O sNN Ph Protein] XProtein] X-(Protein OH OH
OH
4 00 N H HO 0 rLVS 0 LY P N L Ph PrtiX-n ProteinX] o OH H[Lys X-Protein]
OH
A further experiment to elucidate this reaction involves the reaction of a compound of the formula I, N-phenacylthiazolium bromide, with 1-phenyl- 1,2-propanedione to produce the predicted fission product, benzoic acid. The reaction between Nphenacylthiazolium bromide and 1-phenyl-1,2-propanedione was rapid and readily proceeded, confirming this possible mechanism.
Once early, glucose-derived addition products form on proteins, further reactions can ensue to effect a covalent, protein-protein crosslinking reaction. In this regard, a compound of the formula I, N-phenacylthiazolium bromide, was allowed to react with the AGE-crosslinks that form when AGE-modified BSA (AGE-BSA) is allowed to react with unmodified, native collagen. This resulted in a concentration-dependent release of BSA from the pre-formed AGE-mediated complexes. Again, this study confirmed that a significant portion of the AGE-crosslinks that form under experimental conditions consist of an a-diketone or related structure that is susceptible to cleavage by the advantageous bidnttate- type molecules of the compounds of formula I under physiological conditions.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTfUS96/00663 To confirm that the same situation occurs in vivo, isolated collagen from the tail tendons of rats which had been diabetic for 32 weeks were treated with a compound of the formula I, N-phenacylthiazolium bromide, prior to cyanogen bromide digestion and gel electrophoresis analysis. The subsequent electrophoresis revealed that the treated collagen was indistinguishable from untreated, non-diabetic (control) collagen, in marked contrast to the AGE-modified, highly crosslinked, digestion-resistant collagen that is typically isolated from diabetic animals.
The present invention likewise relates to methods for inhibiting the formation of advanced glycosylation endproducts, and reversing the level of already formed advanced glycosylation endproducts, which comprise contacting the target molecules with a composition of the present invention. In the instance where the target proteins are contained in foodstuffs, whether of plant or animal origin, these foodstuffs could have applied to them by various conventional means a composition containing the present agents.
In the food industry, sulfites were found years ago to inhibit the Maillard reaction and are commonly used in processed and stored foods. Recently, however, sulfites in food have been implicated in severe and even fatal reactions in asthmatics. As a consequence, the sulfite treatment of fresh fruits and vegetables has been banned. The mechanism for the allergic reaction is not known. Accordingly, the present compositions and agents offer a nontoxic alternative to sulfites in the treatment of foods in this manner.
As is apparent from a discussion of the environment of the present invention, the present methods and compositions hold the promise for arresting, and to some extent reversing, the aging of key proteins both in animals and plants, and concomitantly, conferring both economic and medical benefits as a result thereof. In the instance of foodstuffs, the administration of the present composition holds the promise for retarding food spoilage thereby making foodstuffs of increased shelf life and greater availability to consumers. Replacement of currently-used preservatives, such as sulfur dioxide known to cause allergies and asthma in humans, with non-toxic, biocompatible compounds is a further advantage of the present invention.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 21 The therapeutic implications of the present invention relate to the arrest, and to some extent, the reversal of the aging process which has, as indicated earlier, been identified and exemplified in the aging of key proteins by advanced glycosylation and crosslinking. Thus, body proteins, and particularly structural body proteins, such as collagen, elastin, lens proteins, nerve proteins, kidney glomerular basement membranes and other extravascular matrix components would all benefit in their longevity and operation from the practice of the present invention. The present invention thus reduces the incidence of pathologies involving the entrapment of proteins by cross-linked target proteins, such as retinopathy, cataracts, diabetic kidney disease, glomerulosclerosis, peripheral vascular disease, arteriosclerosis obliterans, peripheral neuropathy, stroke, hypertension, atherosclerosis, osteoarthritis, periarticular rigidity, loss of elasticity and wrinkling of skin, stiffening of joints, glomerulonephritis, etc. Likewise, all of these conditions are in evidence and tend to occur at an accelerated rate in patients afflicted with diabetes mellitus as a consequence of this hyperglycemia. Thus, the present therapeutic method is relevant to treatment of these and related conditions in patients either of advanced age or those suffering from one of the mentioned pathologies.
Molecular cross-linking through advanced glycosylation product formation can decrease solubility of structural proteins such as collagen in vessel walls and can also trap serum proteins, such as lipoproteins to the collagen. Also, this may result in increased permeability of the endothelium and consequently covalent trapping of extravasated plasma proteins in subendothelial matrix, and reduction in susceptibility of both plasma and matrix proteins to physiologic degradation by enzymes. For these reasons, the progressive occlusion of diabetic vessels induced by chronic hyperglycemia has been hypothesized to result from excessive formation of sugarderived and particularly, glucose-derived cross-links. Such diabetic microvascular changes and microvascular occlusion can be effectively prevented and reversed by chemical inhibition and reversal of the advanced glycosylation product formation utilizing a composition and the methods of the present invention.
Studies indicate that the development of chronic diabetic damage in target organs is primarily linked to hyperglycemia so that tight metabolic control would delay or even prevent end-organ damage. See Nicholls et al., Lab. Invest., 60, No. 4, p. 486 (1989), SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 22 which discusses the effects of islet isografting and aminoguanidine in murine diabetic nephropathy. These studies further evidence that aminoguanidine diminishes aortic wall protein cross-linking in diabetic rats and confirm earlier studies by Brownlee et al., Science, 232:1629-1632 (1986) to this additional target organ of complication of diabetes. Also, an additional study showed the reduction of immunoglobulin trapping in the kidney by aminoguanidine (Brownlee et al., Diabetes, 35(1):42A (1986)).
Further evidence in the streptozotocin-diabetic rat model that aminoguanidine administration intervenes in the development of diabetic nephropathy was presented by Brownlee et al., 1988, supra, with regard to morphologic changes in the kidney which are hallmarks of diabetic renal disease. These investigators reported that the increased glomerular basement membrane thickness, a major structural abnormality characteristic of diabetic renal disease, was prevented with aminoguanidine.
Taken together, these data strongly suggest that inhibition and reversal of the formation of advanced glycosylation endproducts (AGEs), by the teaching of the present invention, may prevent, as well as to some extent reverse late, as well as early, structural lesions due to diabetes, as well as changes during aging caused by the formation of AGEs.
Diabetes-induced changes in the deformability of red blood cells, leading to more rigid cell membranes, is another manifestation of cross-linking and aminoguanidine has been shown to prevent it in vivo. In such studies, New Zealand White rabbits, with induced, long-term diabetes are used to study the effects of a test compound on red blood cell (RBC) deformability The test compound is administered at a rate of 100 mg/kg by oral gavage to diabetic rabbits.
A further consequence of diabetes is the hyperglycemia-induced matrix bone differentiation resulting in decreased bone formation usually associated with chronic diabetes. In animal models, diabetes reduces matrix-induced bone differentiation by SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIS96/00663 23 In the instance where the compositions of the present invention are utilized for in vivo or therapeutic purposes, it may be noted that the compounds or agents used therein are biocompatible. Pharmaceutical compositions may be prepared with a therapeutically effective quantity of the agents or compounds of the present invention and may include a pharmaceutically acceptable carrier, selected from known materials utilized for this purpose. Such compositions may be prepared in a variety of forms, depending on the method of administration. Also, various pharmaceutically acceptable addition salts of the compounds of Formula I may be utilized.
A liquid form would be utilized in the instance where administration is by intravenous, intramuscular or intraperitoneal injection. When appropriate, solid dosage forms such as tablets, capsules, or liquid dosage formulations such as solutions and suspensions, etc., may be prepared for oral administration. For topical or dermal application to the skin or eye, a solution, a lotion or ointment may be formulated with the agent in a suitable vehicle such as water, ethanol, propylene glycol, perhaps including a carrier to aid in penetration into the skin or eye. For example, a topical preparation could include up to about 10% of the compound of Formula I. Other suitable forms for administration to other body tissues are also contemplated.
In the instance where the present method has therapeutic application, the animal host intended for treatment may have administered to it a quantity of one or more of the agents, in a suitable pharmaceutical form. Administration may be accomplished by known techniques, such as oral, topical and parenteral techniques such as intradermal, subcutaneous, intravenous or intraperitoneal injection, as well as by other conventional means. Administration of the agents may take place over an extended period of time at a dosage level of, for example, up to about 30 mg/kg.
As noted earlier, the invention also extends to a method of inhibiting and reversing the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration to a subject in need of such therapy an amount effective to inhibit and reverse the formation of advanced glycosylation endproducts of a composition comprising an agent of structural Formula I.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 24 The nonenzymatic browning reaction which occurs in the oral cavity results in the discoloration of teeth. Presently used anti-plaque agents accelerate this nonenzymatic browning reaction and further the staining of the teeth. Recently, a class of cationic anti-microbial agents with remarkable anti-plaque properties have been formulated in oral rinses for regular use to kill bacteria in the mouth. These agents, the cationic antiseptics, include such agents as alexidine, cetyl pyridinium chloride, chlorhexidine gluconate, hexetidine, and benzalkonium chloride.
Tooth staining by chlorhexidine and other anti-plaque agents apparently results from the enhancement of the Maillard reaction. Nordbo, J. Dent. Res., 58:1429 (1979) reported that chlorhexidine and benzalkonium chloride catalyze browning reactions in vitro.
Chlorhexidine added to mixtures containing a sugar derivative and a source of amino groups underwent increased color formation, attributed to the Maillard reaction. It is also known that use of chlorhexidine results in an increased dental pellicle. Nordbo proposed that chlorhexidine resulted in tooth staining in two ways: first, by increasing formation of pellicle which contains more amino groups, and secondly, by catalysis of the Maillard reaction leading to colored products.
In accordance with this method, the compounds of Formula I are formulated into compositions adapted for use in the oral cavity. Particularly suitable formulations are oral rinses and toothpastes incorporating the active agent.
In the practice of this invention, conventional formulating techniques are utilized with nontoxic, pharmaceutically acceptable carriers typically utilized in the amounts and combinations that are well-known for the formulation of such oral rinses and toothpastes.
The agent of Formula I is formulated in compositions in an amount effective to inhibit and reverse the formation of advanced glycosylation endproducts. This amount will, of course, vary with the particular agent being utilized and the particular dosage form, but typically is in the range of 0.01% to by weight, of the particular formulation.
The compounds encompassed by Formula I are conveniently prepared by chemical SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 syntheses well-known in the art. Certain of the compounds encompassed by Formula I are well-known compounds readily available from chemical supply houses and/or are preparable by synthetic methods specifically published therefor. For instance, 3,4dimethyl-5-(2-hydroxyethyl)thiazolium iodide; 3-ethyl-5-(2-hydroxyethyl)-4methylthiazolium bromide; 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride; and 3-(carboxymethyl)benzothiazolium bromide are obtainable from Aldrich Chem.
Co.
Compounds described in the chemical and patent literature or directly preparable by methods described therein and encompassed by Formula I are those such as 3-(2phenyl-2-oxoethyl)-4-methylthiazolium bromide and 3-benzyl-5-(2-hydroxyethyl)-4methyl thiazolium chloride [Potts et al., J. Org. Chem., 41:187-191 (1976)].
Certain of the compounds of formula are novel compounds, not heretofore known in the art. These compounds are those represented by the formula Ia Y X R N Z (Ia) R 2 S wherein RI and R2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, acetoxy(lower)alkyl, lower alkyl, lower alkenyl, or RI and R2 together with their ring carbons may be an aromatic fused ring, optionally substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula
O
II
-CH
2
C-R
wherein R is a lower alkyl, alkoxy, hydroxy, amino or an aryl group, said aryl group optionally substituted by one or more lower alkyl,lower alkoxy, halo, dialkylamino, hydroxy, nitro or alkylenedioxy groups; a group of the formula
-CH
2
R'
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 26 wherein R' is hydrogen, or a lower alkyl, lower alkynyl, or aryl group; or a group of the formula O R" I I
-CH
2
C-N-R"'
wherein R" is hydrogen and is a lower alkyl group, optionally substituted by an aryl group, or an aryl group, said aryl group optionally substituted by one or more lower alkyl, halo, or alkoxylcarbonyl groups; or R" and are both lower alkyl groups; with the proviso that at least one of Y and Z is an amino group, and the further proviso that when Y is amino and R 2 and Z are both hydrogen, then R 1 is other than a lower alkyl group; and X is a halide, tosylate, methanesulfonate or mesitylenesulfonate ion.
Other novel compounds are those of formula I wherein Y is a lower alkynylmethyl group or a group of the formula O R" I II
-CH
2
C-N-R"'
wherein R" is hydrogen and is a lower alkyl group, optionally substituted by an aryl group, or an aryl group, said aryl group optionally substituted by one or more lower alkyl, halo, or alkoxylcarbonyl groups; or R" and are both lower alkyl groups.
The compounds of formula I wherein Y is a group of the formula
O
II
-CH
2
C-R
wherein R is a lower alkyl, alkoxy,hydroxy, amino or aryl group; or a group of the formula
-CH
2
R'
wherein R' is hydrogen, or a lower alkyl, lower alkynyl or aryl group; X is a halide, tosylate, methanesulfonate or mesitylenesulfonate ion; can be prepared according to the methods described in Potts et al., J. Org. Chem., 41:187 (1976); and Potts et al., J. Org. Chem., 42:1648 (1977), or as shown in Scheme I below.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 27 Scheme I I I 0 R N II EtOH 2 Z XCH 2 CR R S
O
II
CH C-R 2I 2 R S
(I)
(III)
wherein R1, R2, Z, and R are as hereinabove defined, and X is a halogen atom.
In reaction Scheme I, the appropriate substituted thiazole compound of formula II wherein Ri, R2 and Z are as hereinbefore defined, is reacted with the appropriate halo compound of formula III wherein R and X are as hereinbefore defined, to afford the desired compound of formula I wherein RI, R2, Z, R and X are as hereinbefore defined.
Typically, this reaction is conducted at reflux temperatures for times of about 1-3 hours.
Typically, a polar solvent such as ethanol is utilized for the conduct of the reaction.
The compounds of formula I wherein Y is an amino group can be prepared according to the methods described in Tamura et al., Synthesis, 1 (1977), or as shown below in Scheme II.
SCHEME II
H
Ri N R S O-mesitylene sulfonylhydroxyl am
NH
2 ine I I R N C R NS R) S~ wherein R 1 R2 and Z are as defined hereinabove.
In the reaction shown in Scheme II, typically conducted in an anhydrous polar solvent at room temperatures, typical reaction temperatures range from room temperature to reflux, and typical times vary from 1 to about 4 hours. This reaction affords the mesitylene sulfonate, which can then be optionally converted to other thiazolium salts SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 28 by typical exchange reactions.
The present invention also involves a novel sandwich enzyme immunoassay used to ascertain the ability of test compounds to "break" or reverse already formed advanced glycosylation endproducts by detecting the breaking of AGE (Advanced glycosylation endproduct) moieties from AGE-crosslinked protein. This assay comprises: a) incubation of AGE-modified bovine serum albumin (AGE-BSA) on collagencoated wells of microtiter plates for a period of 2-6 hours at a temperature of 37C b) washing of the wells with PBS-Tween; c) application of the test compounds to the washed wells of step b; d) incubation of the test compounds applied to the washed wells for an additional 12-24 hours at a temperature of about 37 0 C; and e) detection of the AGE-breaking using an antibody raised against AGE-ribonuclease or cross-link breaking with an antibody against BSA.
The following examples are illustrative of the invention.
EXAMPLE 1 3-(2-Methoxv-2-oxoethyl)-thiazolium bromide Thiazole, (850 mg, 10 mmol), methyl bromoacetate (1.52, 10 mmol) and absolute ethanol (50 ml) were refluxed for 2 hours. On cooling, the salt separated and was recrystallized from absolute ethanol to give the title compound (1.59 m.p. 189- 190 0 C (dec).
EXAMPLE 2 3-Amino-4.5-dimethylthiazolium mesitvlenesulfonate An ice cold solution of the 4,5-dimethyl thiazole (2,26 g, 20 mmol) in dry dichloromethane (15 ml) was treated dropwise with a solution of omesitylenesulfonylhydroxylamine (4.3 g, 20 mmol) in dry dichloromethane (15 ml).
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PTU9106 29 After stirring for 2 hours at room temperature, anhydrous ether (10 ml) was added. On cooling, colorless needles of the title product, 3-amino-4,5-dimethyl-thiazolium mesitylenesulfoflate, separated (3.48 m.p. 165-168'C.
EXAMPLE 3 Using the procedures described above in Examples I and 2. the following compounds are prepared.
3-amino-thiazolium mesitylenesulfonate. m.p. 102-1 04'C.
2,3-diamino-thiazolium mesitylenesulfonate, m.p. 173-1 75'C (dec).
3-(2-methoxy-2-oxoethyl)-4,5-dimethylthiazolium bromide, m.p. 184-1 85'C (dec).
3-(2-methoxy-2-oxoethyl)-4-methylthiazolium bromide, m.p. 149-151 VC (dec).
3-(2-phenyl-2-oxoethyl)-4-methylthiazolium bromide, m.p. 21 8-220'C (dec).
3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide, m.p. 212-213'C (dec).
3-amino-4-methyl-thiazolium mesitylene sulfonate, m.p. 143-1 44'C.
3-(2-methoxy-2-oxoethyl)-5-methyl-thiazolium bromide, m.p. 193-1 94'C (dec).
3-(2-phenyl-2-oxoethyl)-5-methyl-thiazolium bromide, m.p. 193-1 94'C.
-bromophenyl]-2-oxoethyl)-thiazolium bromide, m.p. 269-270'C (dec).
3-(2-[41I-bromophenyl] -2-oxoethyl)-4-methyl-thiazolium bromide, m.p. 248-249'C (dec).
3-(2-[41 -bromophenylI-2-oxoethyl)-5-methyl-thiazolium bromide, m.p. 216-21 7'C.
3-(2-[41 -bromophenylI-2-oxoethyl)-4,5-dimethylthiazolium bromide, m.p. 223-224'C (dec).
3-(2-methoxy-2-oxoethyl)-4-methyl-5-(2-hydroxyethyl)-thiazolium bromide, m.p.
137-138 0
C.
3-2pey--xehl--ehl--2hdoyty)tizlu bromide, m.p. 180- 18 1 C.
-bromophenyl]-2-oxoethy)-4-methyl5(2-hydroxyethyl)thiazolium bromide, m.p. 251-252'C (dec).
3 ,4-dimethy1-5-(2-hydroxyethyl)-thiazolium iodide, m.p. 85-87C.
3-ethyl-5-(2-hydroxyethyl)-4-methyl thiazolium bromide, m.p. 84-85'C.
3-benzyl-5-(2-hydroxyethyl)-4-mfethyI thiazolium chloride, m.p. 144- 146'C.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 P~TIUS96/00663 3-(2-methoxy-2-oxoethyl)-benzothiazolium bromide, m.p. 144- 145 0 C (dec).
3 -(2-pheny1-2-oxoethy)-benzothiazolium bromide, m.p. 240-241 0 C (dec).
[4 '-bromopheny I)-2-oxoethy I)-benzo-thiazolium bromide, m.p. 261 -262'C (dec).
3-(carboxymethyl)-belzothiazolium bromide m.p. 250'C (dec).
2,3-diamino-benzothiazolium mesitylenesulfonate, m.p. 212-2 14 0 C (dec).
3-(2-amino-2-oxoethyl)-thiazolium bromide, m.p. 205-206'C.
3-(2-amino-2-oxoethyl)-4-methyl-thiazolium bromide, m.p. 220-222'C.
3-(2-amino-2-oxoethyl)-5-methyl-thiazolium bromide, m.p. 179-1 3-(2-amino-2-oxoethyl)-4,5-dimethy-thiazolium bromide, m.p. 147-1 48'C.
3-(2-amino-2-oxoethyl)-belzothiazolium bromide, m.p. 222-223'C.
3-(2-amino-2-oxoethyl)-4-methyl-5-(2-hydroxyethyl)thiazolium bromide, m.p. 182- 183 0
C.
3-amino-5-(2-hydroxyethyI)-4-methy-thiazolium mesitylenesulfonate, m.p. 94-95'C (dec).
3-(2-methyl-2-oxoethyl)thiazolium chloride, m.p. 178-179'C.
3-amino-4-methyl-5-(2-acetoxyethy1)thiazolium mesitylenesulfonate, m.p. 1 18-1 3-(2-phenyl-2-oxoethyl)thiazolium bromide, m.p. 217-21 8 0
C.
3-2mtoy2ooty)4mtyl5(-ctxehltizlu bromide, m.p. 217- 218 0
C.
3-2aio2ooty)4mtyl5(-ctxehltizlu bromide, m.p. 233- 234 0
C.
2-amino-3-(2-methoxy-2-oxoethy)thiazolium bromide, m.p. 191-1 92'C.
2-amino-3-(2-methoxy-2-oxoethy1)beflzothiazolium bromide, m.p. 236-237C.
2-amino-3-(2-amino-2-oxoethy1)thiazolium bromide, m.p. 209-21 0'C.
2-amino-3-(2-amino-2-oxoethy)belzothiazolium bromide, m.p. 234-235*C.
3- [2-(4'-methoxyphenyl)-2-oxoethyII-thiazo~ilium bromide, m.p. 248- 249'C (dec.); 3- [2-(2',4'-dimethoxyphel)-2-oxoethyfl-thiaxo~ilium bromide, m.p. 214- 21 61C (dec.); 3-[2-(4'-fluoropheny-2-oxoethy1]-thiazoliflium bromide, m.p. 209-2 1 0C (dec.); 3-[2-(2',4'-difluoropheny)-2-oxoeethyl1-thiazo~ilium bromide, m.p. 226-228'C (dec.); 3-[2-(4'-diethylaminophel)-2-oxoethy1F-thiazolinium bromide, m.p. 233-235'C (dec.); 3-propargyl-thiazolium bromide, m.p. 64-66'C; SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 31 3-Propargyl-4-methyl thiazolium bromide, m.p. 213-215"C; thiazolium bromide, m.p. 127-129' C; 3-Propargyl-4, 5-dimethyl thiazolium bromide, m.p. 198-200'C; 3-Propargy1-4-methyI-5-(2-hydroxyethy)-thiazoium bromide, m.p. 132-1 34'C; 3-(2-[3'-methoxyphenyI-2-oxoethy)-thiazoium bromide, m.p. 224-225'C; 3-(2-[3'-methoxy phenyll-2-oxoethyl)-4 methyl-5-(2'-hydroxyethyl)- thiazolium.
bromide. m.p. 164-165'C; 3-(2-[3'-methoxyphenyl]-2-oxoethy)-belzothiazolium bromide, m.p. 215- 21 7'C; 2,3-diamino-4-chlorobenzothiazolium mesitylenesulfonate, m.p. 228-230'C; 2,3-diarmino-4-methyl-thiazolium mesitylene sulfonate, m.p. 204-205'C; 3-amino-4-methyl-5-vinyl-thiazolium mesitylene sulfonate, m.p. 145- 1 471C; 2,3-diamino-6-chlorobenzothiazolium mesitylenesulfonate, m.p. 244-2461C; 2,6-diamino-benzothiazole dihydrochioride, m.p. 31 8-320'C (dec.); 2,6-diamino-3 [2-(4'-methoxyphenyl)-2-oxoethyl] benzothiazolium bromide. m.p. 243- 245'C (dec.); 2,6-diamino-3 -methoxyphenyl)-2-oxoethyl] benzothiazolium. bromide, m.p. 217- 218'C (dec.); 2,6-diamino-3 [2-(4'-diethylaminophenyl)-2-oxoethyl] benzothiazolium bromide, m.p.
223-225'C (dec.); 2,6-diamino-3(2-(4-bromophenyl)-2-oxoethyl] benzothiazolium bromide, m.p. 258- 259'C (dec.); 2,6-diamino-3 (2-(2-phenyl-2-oxoethyl) benzothiazolium bromide, m.p. 208- 21 0'C (dec.); 2,6-diamino-3 [2-(4'-fluorophelyl-2-oxoethyl] benzothiazolium. bromide, m.p. 251 252 0 C (dec.); 3-acetamido-4-methyl-5-thiazolyl-ethyI acetate mesitylenesulfonate, m.p. syrup material; 2,3-diamino-5-methylthiazolium mesitylenesulfonate, m.p. 149-1 52 0
C;
3-[2-(2'-naphthy)-2-oxoethy]-4-methy1-5-(2'-hydroxyethy1)4hiazolium bromide, m.p. 219-220'C; 3-[2-(3',5'-Di-tert-buty1-4'-hydroxyphefl)-2-oxoethy1-4-methyl[S( 2 hydroxyethyl)thiazolium bromide, m.p. 206-207'C; 3-[2-(2',6'-Dichlorophenethylamilo)-2-oxoethy1I-4-methyb5-( 2 hydroxyethyl)- SUBSTITUTE SHEET (RULE 26) M- WO 96/22095 WO 9622095PCTIUS96/00663 32 thiazolium-bromide, m.p. 193-195'C; 3-[2-Dibuty lamino-2-oxoethyl]-4-methyl-5-(2'-hydroxyethyl)-thiazolium bromide, m.p. 78-80'C; 3-[2-4'-carbethoxyanilino)-2-oxoethyl]-4-methyl-5-(2'-hydroxyethyl)- thiazolium bromide, m.p. 204-206'C; 3-[2-(2',6'-Diisopropylanilino)-2-oxoethyl]-4-methyl-5-(2'-hydroxyethyl)- thiazolium bromide, m.p. 166-168*C; 3-amino-4-methyl- 5-[2(2',6'-dichlorobenzyloxy)ethyl]-thioazolium mesitylenesulfonate, m.p. 164-1 66'C; 3-[2-(4'-carbmethoxy-3'-hydroxyanilino)-2-oxoethyl]-4-methyl-5-(2'- hydroxyethyl)-, thiazolium bromide, m.p. 222-223'C; 2,3-Diamino-4,5-dimethyl thiazolium mesitylene sulfonate, m.p. 166- 1 68 0
C;
2,3-Diamino-4-methyl-5-hydroxyethyl-thiazolium mesitylene sulfonate, m.p. 132- 134'C; 2,3-Diamino-5-(3',4'-trimethylenedioxy phenyl) thiazolium mesitylene sulfonate, m.p.
224-226'C; 3 I ,4'-benzodioxan-6-yl)-2-oxoethyl]-4-methyl-5-(2'-hydroxyethyl)- thiazolium bromide, m.p. 196-198 0
C;
3-[2-(3',4'-trimethylenedioxyphenyl)-2-oxoethyll-4-methyl-5-(2'- hydroxyethyl)thiazolium bromide, m.p. 164-166'C; 1',4-benzodioxan-6-yl]-2-oxoethyl)-thiazolium bromide, m.p. 238- 239'C; 3-[2-(3',4'-trimethylenedioxyphenyl)-2-oxoethyl]-thiazolium bromide, m.p. 246- 248'C (dec.); 3-[2-(3',5'-di-tert-butyl-4'-hydroxyphenyl)-2-oxoethyl]-thiazolium bromide, m.p.
3-[2-(3',5'-di-tert-butyl-4'-hydroxyphenyl)-2-oxoethyl]-4-methyl-thiazolium bromide, m.p. 226-228' C (dec.); 3-[2-(3',5'-di-tert-butyl-4'-hydroxyphenyl)-2-oxoethyl]-5-methyl-thiazolium bromide, m.p. 210-211V C; 3-[2-(3',5'-di-tert-butyl-4'-hydroxypheflyl)-2-oxoethyl]-4,5-dimethyl- thiazolium bromide, m.p. 243-244'C (dec.); 3-[2-(3',5'-di-tert-butyl-4'-hydroxyphenyl)-2-oxoethyl]-benzothiazolium bromide, m.p.
239-294'C (dec.); 1 -methyl-3-[2-(3',5'-di-tert-butyl-4'-hydroxyphenyl)-2-oxoethyl]- imidazolium SUBSTITUTE SHEET (RULE 26) WO 96/22095 PTU9106 PCTIUS96/00663 33 bromide, m.p. 148-150'C; 3-[2-(4'-n-pentylphenyl)-2-oxoethyl]-thiazolinium bromide, m.p. 21 8-220 0 C (dec.); 3-[2-(4'-n-pentylphenyl)-2-oxoethyl]-4-methyl-5-(2'-hydroxyethyl)- thiazolinium bromide, m.p. 178-180'C (dec.); 3-[2-4'-diethylaminopheny1)-2-oxoethylI-4-Inethy1-5-(2'-hydroxyethyl)- thiazolinium bromide, m.p. 184-186 0 C (dec.); 3-(2-phenyl-2-oxoethyl)-4-methyl-5-vinyl-thiazolium bromide, m.p. 176- 1 77'C; 3- [2-(3',5'-tert-butyl-4'-hydroxyphenyl)-2-oxoethyl)-4-methyl-5-viflyl- thiazolium bromide, m.p. 208-209' C; 3-(2-tert-butyl-2-oxoethyl)-thiazolium bromide, m.p. 21 1-212'C; 3-(2-tert-butyl-2-oxoethyl)-4-methyl-5-(2'-hydroxyethyl)-thiazolium bromide, m.p.
186- 187'C; 3-(3'-methoxybenzyl)-4-methyl-5-(2'-hydroxyethyl)-thiazolium chloride, m.p. 135- 136'C; 3-(2',6'-dichlorobenzyl)-4-methyl-5-(2-hydroxyethyl)-thiazolium chloride, m.p. 192- 194'C; 3-(2'-nitrobenzyl)-4-methyl-5-(2'-hydroxyethyl)-thiazolium bromide, m.p. 215-21 6'C; 3 [2-(4'-chlorophenyl)-2-oxoethyl]-thiazolium bromide, m.p. 239-241' 0 C (dec.); 3 [2-(4'-chlorophenyl)-2-oxoethyll-4-methyl-5-(2'-hydroxyethyl)-thiazolium bromide, m.p. 240-251 'C and 3 [2-(4'-methoxyphenyl)-2-oxoethyll-4-methyl-5-(2'hydroxyethyl)-thiazolium bromide, m.p. 229-231 PC (dec.).
EXAMPLE 4 mg/tablet Compound of Formula 1 Starch Mannitol Magnesium stearate 2 Stearic The compound, a portion of the starch and the lactose are combined and wet granulated SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 34 with starch paste. The wet granulation is placed on trays and allowed to dry overnight at a temperature of 45 0 C. The dried granulation is comminuted in a comminutor to a particle size of approximately 20 mesh. Magnesium stearate, stearic acid and the balance of the starch are added and the entire mix blended prior to compression on a suitable tablet press. The tablets are compressed at a weight of 232 mg. using a 11/32" punch with a hardness of 4 kg. These tablets will disintegrate within a half hour according to the method described in USP XVI.
EXAMPLE Lotion mg/g Compound of Formula I Ethyl alcohol 400.0 Polyethylene glycol 400 300.0 Hydroxypropyl cellulose Propylene glycol to make 1.0 g EXAMPLE 6 Oral Rinse Compound of Formula I: 1.4 Chlorhexidine gluconate 0.12% Ethanol 11.6% Sodium saccharin 0.15% FD&C Blue No. 1 0.001% Peppermint Oil 0.5 Glycerine 10.0 Tween 60 0.3 Water to 100 EXAMPLE 7 SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 Toothpaste Compound of Formula I: 5.5 Sorbitol, 70% in water 25 Sodium saccharin 0.15 Sodium lauryl sulfate 1.75 Carbopol 934, 6% dispersion in 15 Oil of Spearmint 1.0 Sodium hydroxide, 50% in water 0.76 Dibasic calcium phosphate dihydrate 45 Water to 100 EXAMPLE 8 CROSS-LINKING INHIBITION ASSAY The following method was used to evaluate the ability of the compounds of the present invention to inhibit the cross-linking of glycated bovine serum albumin (AGE-BSA) to the rat tail tendon collagen-coated 96-well plate.
The AGE-BSA was prepared by incubating BSA at a concentration of 200 mg per ml with 200 mM glucose in 0.4M sodium phosphate buffer, pH 7.4 at 37 0 C for 12 weeks.
The glycated BSA was then extensively dialyzed against phosphate buffer solution (PBS) for 48 hours with additional 5 times buffer exchanges. The rat tail tendon collagen coated plate was blocked first with 300 pl. of superbloc blocking buffer (Pierce #37515X) for one hour. The blocking solution was removed from the wells by washing the plate twice with PBS-Tween 20 solution (0.05% Tween 20) using a NUNC-multiprobe or Dynatech ELISA-plate washer. Cross-linking of AGE-BSA (1 to 10 glg per well depending on the batch of AGE-BSA) to rat tail tendon collagen coated plate was performed with and without the testing compound dissolved in PBS buffer at pH 7.4 at the desired concentrations by the addition of 50 pl1 each of the AGE- BSA diluted in PBS or in the solution of test compound at 37 0 C for 4 hours.
Unbrowned BSA in PBS buffer with or without testing compound were added to the SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 36 separate wells as the blanks. The un-cross-linked AGE-BSA was then removed by washing the wells three times with PBS-Tween buffer. The amount of AGE-BSA cross-linked to the tail tendon collagen-coated plate was then quantitated using a polyclonal antibody raised against AGE-RNase. After a one-hour incubation period, AGE antibody was removed by washing 4 times with PBS-Tween.
The bound AGE antibody was then detected with the addition of horseradish peroxidase-conjugated secondary antibody goat anti-rabbit immunoglobulin and incubation for 30 minutes. The substrate of 2,2-azino-di(3-ethylbenzthiazoline sulfonic acid) (ABTS chromogen) (Zymed #00-2011) was added. The reaction was allowed for an additional 15 minutes and the absorbance was read at 410 nm in a Dynatech plate reader.
The inhibition of each test compound was calculated as follows.
inhibition S[Optical density (without compound) optical density (with compound)]/optical density (without compound)} x 100% The IC 50 values or the inhibition at various concentrations by test compounds is as follows: SUBSTITUTE SHEET (RULE 26) Test Compound ICORelative Cross-link (mM Inhibition (at 10 mM) Inhibition Data 3-amino-4, 5-dimethylaminothiazolium 2.8 mesitylenesul fonate 2, 3-diaminothiazolinium mesitylenesulfonate >.10 2716 /3 3- (2-methoxy-2-oxoethyl) -thiazolium bromide 0.25
C,,
cn3- (2-methoxy-2-oxoethyl) -4,S-dimethylthiazolium 4110 bromide 0.48 M 3- (2-methoxy-2-oxoethyl) -4-methyithiazolium bromide 58!k ci, M 3- (2-phenyl-2-oxoethyl) -4-methyithiazolium bromide 5.6 C= 3- (2-phenyl-2-oxoethyl) -4,5-dimethyithiazolium bromide 37%
I-
3-amino-4-methylthiazolium mesitylenesulfonate 4 6%1 3- (2-methoxy-2-o’xoethyl) -5-methyithiazolium bromide 3.2 3- (2-phenyl-2-oxoethyl) -5-methyithiazolium bromide 12.6 3- -bromophenyl) -2-oxoethyl] -4-methylthiazolium bromide 37%k 3- (4 ‘bromophenyl) -2-oxoethyll -4,5-dimethylthiazolium bromide 2.92 3- (2-methoxy-2-oxoethyl) -4-methyl-5- (2hydroxyethyl) thiazolium bromide 3- (2-phenyl-2-oxoethyl) -4-methyl-5- (2hydroxyethyl) thiazolium bromide 3-[2-(4′-bromophenyl)-2-oxoethylI-4-methyl-5- (2-hydroxyethyl) thiazolium bromide 3- (2-methoxy-2-oxoethyl)beflzothiazolium bromide lQ 3- (carboxymethyl)benzothiazolium bromide (diamino)benzothia’zolium mesitylenesulfonate 10 3- (2-amino-2-oxoethyl)thiazolium bromide rn3- (2-amino-2-oxoethyl) -4-methyithiazolium bromide =03- (2-amino-2-oxoethyl) -5-methyithiazolium bromide pa3- (2-amino-2-oxoethyl)4, 5-dimethyithiazolium bromide 0) 3- (2-amino-2-oxoethyl)beflzothiazolium bromide 3-(2-amillo-2-oxoethyl)4-mTethyl- 5 -1 2 hydroxyethyl) thiazolium bromide (2-hydroxyethyl) -4-methyithiazolium mesitylenesul fonate 3- (2-pheny1-2-oxoethy1)thiazolium bromide 3- -methoxyphenyll -2-ox’oethyl) -thiazolium bromide 3 8 P 36!k 2.95 >10 0 .0749 0.53 0.7 0 .0289 9.9 0.02 1.42 3.6 x 10-5 11. 1 3 16% 34% 29% 2, 3-diamino-4-chorobelzothiazoiurti mesitylenesulfonate 2, 3-diamino-4-methyl-thiazolium mesitylene sulfonate 3-amino-4-methy1-5-vifl-thiazolium mesitylene sulfonate 2,3-diamino-6-chlorobeflzothiazolium mesitylenesulfonate 2,6-diamino-32-(4-methoxyphelyl) -2-oxoethyl] cn benzothiazolium bromide cn 2,6-diamino-3(2-(4-bromfophefyl)l2-oxoethyl] A benzothiazolium bromide Ill 2,6-diamino-3(2-(4-ftioropheflyl-2-oxoethylI T 4: 10benzothiazolium bromide !q 2, 3-diamino-5-methylthiazolium mesitylenesulfonate :v 3- [2-(2′-naphthy1)-2-oxoethyl]-4-methy1-5-i2′-hydroxyrn ethyl) -thiazolium bromide .n 3- (2-Dibutylamino-2-oxoethyl] -4-methyl-5-(1hydroxyethyl) -thiazolium bromide 3- -carbethoxyanililo) -2-oxoethyl] -4-methyl- (2′-hydroxyethyl) -thiazolium bromide 3- ,6′-Diisopropylaniiino) -2-oxoethyl] -4- -hydroxyethyl) -thiazolium bromide 3-amino-4-methyl-5- -dichlorobenzyloxy) ethyl] thioazolium mesitylenesulfonate 3- -carbmethoxy-3′ -hydroxyanilino) -2-oxoethyl] -hydroxyethyl) -thiazolium bromide 2, 3-Diamino-4, 5-dimethyl thiazolium mesitylene sulfonate 3 3 11.3 23.2 (2 mm) 61%.
0. 8k (10 MM) 8. 8% (1 MM) 19% 26.5%; (3 mm) 1 .76 39t 2, 3-Diamino-4-methyl-S-hydroxyethyl-thiazolium mesitylene sulfonate 2,3-Diamino-5- (3’1′-trimethylenedioxy phenyl) thiazolium mesitylene sulfonate 3[2-(1′,4′-benzodioxafl-6-y1)-2-oxoethyl]-4- -hydroxyethyl) -thiazolium bromide 3- ,4′-trimethylenedioxyphenyl) -2-oxoethyl] -hydroxyethyl) -thiazolium bromide cn3- ,4′-trimethylenedioxyphenyl) -2-oxoethyl] thiazolium bromide 3-[2-(3′,S’-di-tert-buty1-4′-hydroxypheflV2- C= oxoethyl] -4-methyl-thiazoliun bromide rn 3-[2-(3′,5′-di-tert-butyl-4′-hydroxyphel)-2cn oxoethyl] -5-methyl-thiazolium bromide 3-[2-(3′,-51’di-tert-butyl-4′-hydroxyphel)-2oxoethyl] -4,5-dimethyl-thiazolium bromide i-methyl-3-[2-(3′ ,5′-di-tert-butyl-4′-hydroxyphelyl)- CD 2-oxoethy1]-imidazoiumT bromide 3- -n-pentylphenyl) -2-oxoethyll -thiazolinium bromide 3- [2-(4′-n-pentylpheny1)-2-oxoethy1]-4-methyl-S- -hydroxyethyl) -thiazolinium bromide 3- -diethylaminophelYl) -2-oxoethyl) -hydroxyethyl) -thiazolinium bromide 3- (2-phenyl-2-oxoethyl) -4-methyl-5-viflyl-thiazolium bromide 3- ,5′-tert-butyl-4′ -hydroxyphenyl) -2-oxoethyl) bromide 18% 40% 3mM 13%* 4.4 4 24k 0.3mM 69t 1mM 0 .78 0.16 1 .53 2.8
ND
ND
52% 3-mM WO 96/22095 PCT/US96/00663 The above experiments suggest that this type of drug therapy may have benefit in reducing the pathology associated with the advanced glycosylation of proteins and the formation of cross-links between proteins and other macromolecules. Drug therapy may be used to prevent the increased trapping and cross-linking of proteins that occurs in diabetes and aging which leads to sequelae such as retinal damage, and extra-vascularly, damage to tendons, ligaments and other joints. This therapy might retard atherosclerosis and connective tissue changes that occur with diabetes and aging. Both topical, oral, and parenteral routes of administration to provide therapy locally and systemically are contemplated.
EXAMPLE 9 CROSS-LINK BREAKING ASSAY In order to ascertain the ability of the compounds of the instant invention to «break» or reverse already formed advanced glycosylation endproducts, a novel sandwich enzyme immunoassay was developed which detects breaking of AGE (Advanced glycosylation endproduct) moieties from AGE-crosslinked protein. The assay utilizes collagen-coated 96 well microtiter plates that are obtained commercially.
AGE-modified protein (AGE-BSA), prepared, for instance, as in Example 8, above, is incubated on the collagen-coated wells for four hours, is washed off the wells with PBS-Tween and solutions of the test compounds are added. Following an incubation period of 16 hours (37 0 C) cross-link-breaking is detected using an antibody raised against AGE-ribonuclease or with an antibody against BSA. Positive results in this assay indicate compounds that are capable of reducing the amount of AGE-BSA previously crosslinked to the collagen by breaking the crosslinks and allowing the liberated material to be flushed away in subsequent washing steps. Details of the assay are as follows:
MATERIALS
Immunochemicals and Chemicals Bovine Serum Albumin (Type (BSA) Calbiochem Dextrose Superbloc, Pierce, Inc.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 41 Rabbit anti-Bovine Serum Albumin Horseradish Peroxidase (HRP)-Goat-anti-rabbit), Zymed HRP substrate buffer, Zymed ABTS chromogen, Zymed Phosphate Buffer Saline Tween 20, Sigma Equipment ELISA Plate Washer, Dynatech ELISA Plate Reader, Dynatech Precision Water Bath Coming digital pH meter Glassware and Plasticware Finneppette Multichannel Pipettor, Baxter Eppendorf pipettes, Baxter Eppendorf repeater pipette, Baxter Pipetter tips for Finneppetter, Baxter Pipetter tips for Eppendorf, Baxter Glass test tubes, 13×100 mm; Baxter Mylar Sealing Tape for 96 well plates, Coming Biocoat Cellware Rat Tail Collagen Type-1 coated 96-well plates, Collaborative Biomedical Products
METHODS
Preparation of solutions and buffers 1. AGE-BSA stock solutions were prepared as follows. Sodium phosphate buffer (0.4 M) was prepared by dissolving 6 grams of monobasic sodium phosphate in 100 ml of distilled water, 7 grams of dibasic sodium phosphate (0.4 M) in 100 ml of distilled water and adjusting the pH of the dibasic solution to 7.4 with the monobasic solution. Sodium azide (0.02 grams) was added per 100 ml volume to inhibit bacterial growth. The BSA solution was prepared as follows: 400 mg of Type V BSA (bovine serum albumin) was added for each ml of sodium phosphate buffer SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 42 (above). A 400 mM glucose solution was prepared by dissolving 7.2 grams of dextrose in 100 ml of sodium phosphate buffer (above). The BSA and glucose solutions were mixed 1:1 and incubated at 37 0 C for 12 weeks. The pH of the incubation mixture was monitored weekly and adjusted to pH 7.4 if necessary. After 12 weeks, the AGE-BSA solution was dialyzed against PBS for 48 hours with four buffer changes, each at a 1:500 ratio of solution to dialysis buffer. Protein concentration was determined by the micro-Lowry method. The AGE-BSA stock solution was aliquoted and stored at -20 0 C. Dilute solutions of AGE-BSA were unstable when stored at -20 0
C.
2. Working solutions for crosslinking and breaking studies were prepared as follows. Test compounds were dissolved in PBS and the pH was adjusted to pH 7.4 if necessary. AGE- BSA stock solution was diluted in PBS to measure maximum crosslinking and in the inhibitor solution for testing inhibitory activity of compounds. The concentration of AGE- BSA necessary to achieve the optimum sensitivity was determined by initial titration of each lot of AGE-BSA.
3. Wash buffer («PBS-Tween») was prepared as follows. PBS was prepared by dissolving the following salts in one liter of distilled water: NaCI, 8 grams; KCI, 0.2 gram, KH 2
PO
4 1.15 grams; NaN 3 0.2 gram. Tween-20 was added to a final concentration of 0.05% (vol/vol).
4. Substrates for detection of secondary antibody binding were prepared by diluting the HRP substrate buffer 1:10 in distilled water and mixing with ABTS chromogen 1:50 just prior to use.
Assay procedures 1. Biocoat plates were blocked with 300 tl of «Superbloc». Plates were blocked for one hour at room temperature and were washed with PBS-Tween three times with the Dynatech platewasher before addition of test reagents.
2. Each experiment was set up in the following manner. The first three wells of the Biocoat plate were used for the reagent blank. Fifty microliters of solutions SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTfUS96/00663 43 AGE-BSA were added to test wells in triplicate and only PBS in blank wells.
The plate was incubated at 37°C for four hours and washed with PBS-Tween three times. Fifty microliters of PBS was added to the control wells and 50 tl of the test «AGE Cross-link breaker» compound was added to the test wells and blank. The plate was incubated overnight (approximately 16 hours) with the test «AGE Cross-link breaker» compound, followed by washing in PBS before addition of primary antibody (below).
3. Each lot of primary antibody, either anti-BSA or anti-RNase, was tested for optimum binding capacity in this assay by preparing serial dilutions (1:500 to 1:2000) and plating 50 g1 of each dilution in the wells of Biocoat plates. Optimum primary antibody was determined from saturation kinetics. Fifty microliters of primary antibody of appropriate dilution, determined by initial titration, was added and incubated for one hour at room temperature. The plate was then washed with PBS-Tween.
4. Plates were incubated with the secondary antibody, HRP-(Goat-anti-rabbit), which was diluted 1:4000 in PBS and used as the final secondary antibody. The incubation was performed at room temperature for thirty minutes.
5. Detection of maximum crosslinking and breaking of AGE crosslinking was performed as follows. HRP substrate (100ul) was added to each well of the plate and was incubated at 37 ‘C for fifteen minutes. Readings were taken in the Dynatech ELISA-plate reader. The sample filter was set to and the reference filter was set to STANDARD OPERATING
PROCEDURE
Preliminary Steps 1. Titrate each new lot of AGE-BSA preparation as described in Table 4 and determine the optimum AGE-BSA concentration for the ELISA assay fromsaturation kinetics.
2. At the beginning of the day, flush the plate washer head with hot water,rinse with distilled water and 50% ethanol. Fill the buffer reservoir of theplate washer with PBS- Tween and purge the system three times before use.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 44 3. Prepare an assay template for setting up the experiment as described under «Assay Setup». below.
Assay Setup I. Warm Superbloc reagent to 37 Add 300 g1 of Superbloc to each well of the Biocoat plate and let stand for sixty minutes at 37 Wash the wells three timeswith PBS-Tween Turn the plate 180 degrees and repeat this wash cycle.
2. Dilute the AGE-BSA in PBS so that 50 gl of the diluted sample will contain the amount of AGE-BSA necessary for minimum crosslinking and inhibition by pimagedine (aminoguanidine), as determined by initial titration described above.
Prepare negative controls by dissolving non-browned BSA in PBS at the same concentration as the AGE-BSA. Add 50 gl of AGE-BSA or BSA to each well which correspond to the «AGE-BSA» and «BSA» labels on the template.
3. Dissolve the test compounds in PBS at 30 mM concentration for preliminary evaluation. The pH must be checked and adjusted to 7.4 when necessary. Pretreat the collagen-coated plates with AGE-BSA to obtain maximum crosslinking. Prepare negative controls for inhibition experiments by dissolving BSA in the inhibition solution at the same protein concentration as that used for AGE-BSA. Add 50 pg of AGE-BSA or BSA in the inhibitor solutions to the wells which correspond to «ALT# AGE-BSA and to «ALT# blank», respectively, on the template. Incubate the plate at 37 ‘C for four hours. Following covalent binding of AGE-BSA to the plates, wash the plates with PBS-Tween in preparation of the detection reaction (below).
4. Binding of primary antibody to the Biocoat plates is carried out as follows. At the end of the four hour incubation, the wells are washed with PBS-Tween.
Appropriate dilutions (as determined by initial titration) of the rabbit-anti-AGE- RNase or rabbit-anti-BSA antibodies were prepared in PBS, and 50 pl is added to each well and the plate is allowed to stand at room temperature for sixty minutes.
Secondary antibody binding wells are washed with PBS-Tween and 50 microliters SUBSTITUTE SHEET (RULE 26)
I
WO 96/22095 PCT/US96/00663 HRP (Horseradish Periodase) (Goat anti-rabbit serum) diluted to 1-4000 in PBS and is added to each well. The plate is allowed to stand at room temperature for 30 minutes.
6. Color development was carried out as follows. Plates are washed as in Step 4 above. Dilute the HRP-substrate buffer 1:10 in water. Add 200 l1 of ABTS solution, mix well and add 100 tl of this reagent to each well. Incubate the plate at 37 0 C for minutes. Read the optical density at 410 nm with the sample filter set to and the reference filter set to on the Dynatech ELISA plate reader. Calculate the percent inhibition by the compound as described above. Compounds which are found to reduce the amount of immunoreactivity are considered to be therapeutically useful insofar as they reverse and reduce the levels of advanced glycosylation endproducts.
SUBSTITUTE SHEET (RULE 26) Test Compound IpSO -(mM) Anti -AGE/Ant i-BSA 3-aminothiazolium mesitylenesulfonate 3-amino-4, mesitylenesulfonate 2, 3-diaminothiazolinium mesitylenesulfonate CO3- (2-methoxy-2-oxoethyl) -thiazolium bromide w Zn3- (2-methoxy-2-oxoethyl) bromide M3- (2-methoxy-2-oxoethyl) -4-methyithiazolium bromide Ci, j 3- (2-phenyl-2-oxoethyl) -4-methyithiazolium bromide q3- (2-phenyl-2-oxoethyl) -4,5-dimethylthiazolium bromide 3-amino-4-methylthiazolium mesitylenesulfonate 3- (2-methoxy-2-oxoethyl) -5-methyithiazolium bromide 3- -bromophenyl) -2-oxoethyl] thiazolium bromide 3-(2-phenyl-2-oxoethyl)-4-methyl-S-(2hydroxyethyl) thiazolium bromide (2-hy droxyethyl) -4-methyithiazolium chloride 3- (2-methoxy-2-oxoethyl)benzothiazolium bromide 3- (carboxymethyl)benzothiazolium bromide 2,3- (diamino)benzothiazolium mesitylenesulfonate 3- (2-amino-2-oxoethyl) -4-methyithiazolium bromide 3- (2-amino-2-oxoethyl)4,5-dimethylthiazolium bromide 0 .005/3 .0 0.28/0.18 0.23/0.30 14.3/112 .p 0 .42/0 .55 1 .20/25. 9 4 .70/38.6 BreakingT Anti-AGE /Anti -BSA (at mM) 71%/67t 63t/44t 79t/90% 38%/l41% 63/47t 54-0/51% 68*6/66t 56%/ND 55%/ND 72t/27%i 76%i/25%- 671%/13t 65*/61% 66%/37k 63.7k/17.9!k 87t/54’k 89*1/441; 61t/16%
C
r
K
CF
3- (2-amino-2-oxoethyl)benzothiazolium bromide 0.4/0.5 3-(2-amino-2-oxoethyl)4-methyl-5-(2hydroxyethyl) thiazolium bromide 0.012/0 (2-hydroxyethyl) -4methyithiazolium mesitylenesulfonate 0.18/0.
3-(2-methyl-2-oxoethyl)thiazolium chloride 0.83/0.
S 3- (2-phenyl-2-oxoethyl)thiiazolium bromide 0.020/0 3- -methoxyphenyl] -2-oxoethyl) -thiazolium bromide 2,3-diamino-4-chlorobenzothiazolium mesitylenesulfonate q10 2,3-diamino-4-methyl-thiazolium mesitylenesulfonate 3-amino-4-methyl-5-vinyl-thiazolium mesitylenesulfonate ND/2.0 2, 3-diamino-6-chlorobenzothiazolium mesitylenesulfonate 2,6-diamino-3 -methoxyphenyl) -2-oxoethylI benzothiazolium bromide 2,6-diamino-3(2-(4′-bromophenyl)-2-oxoethylI benzothiazolium bromide 2, 6-diamino-3 -fluorophenyl-2-oxoethyl] benzothiazolium bromide 2, 3-diamino-5-methylthiazolium mesitylenesulfonate 3-[2-(2′-naphthyl)-2-oxoethyl]-4-methyl-5-(2′-hydroxyethyl) -thiazolium bromide 3- [2-Dibutylamino-2-oxoethyl] -4-methyl-5- hydroxyethyl) -thiazolium bromide 2 120 50 75 014 7701/6511 65%/57% 76 %/48!k 56%/93% 73%/98% 22%/44% 21%/26 25%6/30% 51%/74% 25%/51 29%/35% 2716/44% 24-1/40% 14%/17% 52%/61’1 25%/38% 3-12-4′ -carbethoxyanilino) -2-oxoethyl] -4-methyl- -hydroxyethyl) -thiazolium bromide 3- ,6′-Diisopropylanilino) -2-oxoethyll -4- -hydroxyethyl) -thiazolium bromide 3-amino-4-methyl-5- [2(2′,6′-dichlorobenzyloxy)ethyllthicazolium mesitylenesulfonate 3- -carbmethoxy-3′ -hydroxyanilino) -2-oxoethyll co 4-methyl-5- (2′-hiydroxyethyl) -thiazoliumn bromide C/ 2, 3-Diamino-4,5-dimethyl thiazoliun mesitylene sulfonate 10 2,3-Diarnino-4-methyl-5-hydroxyethyl-thiazolium M mesitylene sulfonate
C’,
j 2,3-Diamino-5- A’ -trimethylenedioxy phenyl) mn thiazolium mesitylene sulfonate 3[2-(1′,4′-benzodioxan-6-yl)-2-oxoethyl]-4methyl-5- -hydroxyethyl) -thiazolium bromide c 3- ,4′-trimethylenedioxyphenyl)-2-oxoethyl] -hydroxyethyl) -thiazolium bromide 3- ,4′-trimethylenedioxyphenyl) -2-oxoethyl] thiazolium bromide 3-[2-(3′,5′-di-tert-butyl-4′-hydroxyphenyl)-2oxoethyl] -4-methyl-thiazolium bromide 3- -di-tert-butyl-4′ -hydroxyphenyl) -2oxoethyl] -5-methyl-thiazolium bromide 3- -di-tert-butyl-4′ -hydroxyphenyl) -2oxoethyl] -4,5-dimethyl-thiazolium bromide 1-methyl-3- -di-tert-butyl-4′ -hydroxyphenyl) 2-oxoethyll -imidazolium bromide 4811/5716 31!k/48% 3101/54% 24t/239i 20%/18% 13%/42% (1) 11%i/21% (3) 34%i/0 17%/18% 1411/2-1 (0.3) 65%/69% (1) 56%/38% 3/0.74 M M M M 3- (2-phenyl-2–oxoethyl) bromide 3- 5′ -tert-butyl-4′ -hydroxyphenyl) -2-oxoethyl) bromide 3- (2-tert-butyl-2–oxoethyl) -thiazolium bromide 3-(2-tert-butyl-2-oxoethyl)-4-methyl-5-(2’hydroxyethyl) -thiazolium bromide Co C= 3- (3′-methoxybenzyl)-4-methyl-5-(2′-hydroxyethyl)q thiazolium chloride c41O 3-(2′,6′–dichlorobenzyl)-4-methyl-5-(2′-hydroxyethyl)- M thiazolium chloride
C/)
M 3-(2′-nitrobenzyl)-4-methyl-5-(2′-hydroxyethyl)m thiazolium bromide
M
ND/. .1 62%/82% (1) ND/Q/60% 32%/501 (0.3) 28-0/3706 4t/19% 14%/25t 60-/27% 11%/13% WO 96/22095 PCT/US96/00663 49 EXAMPLE To ascertain the ability of the compounds of the invention to decrease the amount of IgG crosslinked to circulating red blood cells in streptozotocin-induced diabetic rats, was measured by the following assay. The test compounds are administered to the test animals either orally or intraperitoneally, and the blood samples are collected are tested at various times, e.g. 4. 7 or 19 days. after administration to assess efficacy.
Protocol for RBC-IgG assay A. Preparation of Red Blood Cells Blood is collected from the rats in heparinized tubes and spun at 2000 x g for minutes, and the plasma carefully removed. Then, about 5 ml of PBS per ml blood is added, gently mixed, and then spun again. The supernatant is then removed by aspiration. The wash is then repeated two more times. Then, 0.2 to 0.3 ml of packed RBC is withdrawn from the bottom of the tube, using a pipette, and added to the PBS to make a 1 to 10 dilution. This dilution is then further diluted 1 to 25 and 1 to 50 in
PBS.
B. Assay set up.
1. Warm Superbloc to 370 C.
2. Take a plate of Multiscreen-HA, 0.45u. Cellulose ester membrane-sealed 96 well plate (Millipore 3. Wet the wells with 100 ul of PBS.
4. Add 300 ul of superblock to each well and incubate at 37 0 C. for one hour.
5. Place the plate on the Millititer Vacuum holder, turn on the vacuum and press the plate down once for tight hold. The liquids in the wells will be suctioned off. Wash the wells with 300 ul of PBS-Tween 0.05%.
6. Turn off the vacuum and add 100 ul of PBS to each well.
7. Gently vortex the RBC samples and pipette 50 ul to the wells, as per the protocol sheet. Leave first three wells for reagent blanks. Leave another three wells for antibody blank.
8. Suction-off the liquid as above and wash the RBCs twice with PBS.
9. Dilute AP(Rb-anti-rat) (Sigma A-6066), 1 to 25000 in PBS.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 Add 50 ul to the wells and let stand at room temp. for two hours.
11. Suction-off the liquid as above and wash the RBCs twice with PBS.
12. Add pNPP substrate (Img/ml in DEA buffer). 100 ul per well.
13. Let the color develop for two hours at 370 C.
14. Place a 96 well coming micrometer plate in the vacuum chamber.
Place the sample plate on the vacuum manifold. Make sure the bottom of the plate is completely dry.
16. Apply vacuum for about 5 minutes. Add 100 ul of PBS to all wells and apply vacuum again for 5 minutes. Gently lift the plate and make sure that no liquid drops are hanging at the bottom of the plate. If necessary apply vacuum for few more minutes. Read OD of the solution collected in the Coming plate on Dynatech Plate reader Sample filter 1 and Ref.
filter 4.
17. Calculate percent breaking: 100* (OD410 control-OD410 treated)/OD410 control.
Percent inhibition in animals dosed orally at a rate of 10 mg/kg body weight are as listed below: 3 -amino- 4 -methyl-5-vinyl-thiazolium mesitylenesulfonate 11 1 19 days 3-[2-(2′-naphthyl)-2-oxoethyl]-4methyl-5-(2′-hydroxyethyl)-thiazolium bromide 40 24 19 days 3-[2-(3′,5′-di-tert-butyl-4′-hydroxybromide ±15@ 19 days 3 2 -phenyl-2-oxoethyl)-4-methyl-5vinyl-thiazolium bromide 58 21 19 days The extensive degree of reversal of crosslinking observed in these studies underscores two important conclusions by Applicants. First, a large percentage of cross-links formed in vivo are susceptible to attack and cleavage by the dinucleophilic, thiazoliumbased compounds of the present invention, and thus, by inference, that these cross-links comprise an a-diketone segment consistent with the model shown in Schemes A and B. Second, the crosslink-breaking agents of the present invention can act catalytically, in the sense that a single, dinucleophilic thiazolium-based molecule of the present invention can attack and cause the cleavage of more than one glycation cross-link.
EXAMPLE 11 SUBSTITUTE SHEET (RULE 26)
I
WO 96/22095 PCT/US96/00663 51 This example describes the preparation of CNBr peptide maps of rat laid tendon collagen from normal and diabetic animals following treatment with a compound of formula I, 3 2 -phenyl- 2 -oxoethyl)thiazolium bromide (ALT 766). Collagen fibers from streptozotocin diabetic rats and age-matched control animals hydrated in land PBS at 60 0 C for one hour, the soluble collagen was removed and the pellets were washed several times with PBS then treated with 3 2 -phenyl-2-oxoethyl)thiazolium bromide at a concentration of 30mM for 16 hours. Following incubation, the pellets were centrifuged, washed, and treated with CNBr (40mg/ml in formic acid at 30 OC for 48 hours. The CNBr digests were lyophilized repeatedly to remove CNBr and acid and then subjected to SDS-PAGE (20% acrylamide) under reducing conditions (Lanes 1, 2 and 9, MWS; lane 3, 4 and 5, tail tendon collagen from non-diabetic animals with 3 and treated with 3 2 -phenyl-2-oxoethyl)thiazolium bromide, 4 was treated with PBS; lanes 6,7 and 8, collagen from diabetic animals with 6 and 8 treated with 3 -(2-phenyl-2oxoethyl)thiazolium bromide, 7 was treated with PBS). The gels which result are as shown in Figure 1.
EXAMPLE 12 Preparation of AGE-BSA and crosslinked-AGE-BSA: Prepare the following solutions.
1. Buffer: 0.4 M sodium phosphate pH 7.4.
NaH2PO 4 :6g/100ml Na 2 HP0 4 :7g/100ml pH of the monbasic sodium phosphate was adjusted to 7.4 with the dibasic 0.02g sodium axide was added per 100 ml of the buffer.
2. BSA Solution BSA: Calbiochem Type V; 400 mg/ml in the buffer 1. Total volume prepared 50g/125ml. Filtered through a 0.45u filter into a sterile one liter Coming flask.
3. Glucose solution. 400uM Glucose: 400 mM 9g/125ml of buffer. Filtered through a 0.45u filter into one liter Coming sterile flask.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 52 Reaction setup: BSA and glucose solutions (100ml each) were mixed in the one liter Coming sterile flask, screw-capped tight and incubated at 56 0 C. without shaking. The bottle was opened once a week to remove aliquots for testing. Reaction was continued for 9 weeks when AGE-BSA polymer formation was observed.
Breaking the polymer: Pieces of AGE-BSA gel was washed with PBS until no more protein was leached in the supernatant, blotted dry with paper towels. About 50 mg of the washed gel was incubated either with PBs or 10 mm 3 2 -phenyl-2-oxoethyl)thiazolium bromide (ALT 766) overnight at 37 0 C. The supernatants were analyzed by SDS-PAGE and stained with coommassie blue. The resulting gels are shown in Figure 2.
EXAMPLE 13 To further study the ability of AGE crosslink-inhibiting and reversing agents of the present invention to prevent the discoloration of protein on a surface, such as that which occurs on the tooth surface, the following surface browning experiment is performed. As a substitute for a pellicle-covered tooth surface, unexposed and developed photographic paper is used to provide a fixed protein (gelatin, i.e., collagen) surface on a paper backing. Five millimeter circles are punched and immersed for one week at 50 0 C in a solution of 100 mM glucose-6-phosphate in a M phosphate buffer, pH 7.4, containing 3 mM sodium azide. Glucose-6-phosphate is a sugar capable of participating in nonenzymatic browning at a more rapid rate than glucose. In addition to the glucose-6-phosphate, chlorhexidine and/or a compound of Formula I are included. After incubation, the gelatin/paper disks are rinsed with water, observed for brown color, and photographed.
Incubation of the disks in glucose-6-phosphate alone shows slight brown color versus disks soaked in buffer alone. Inclusion of chlorhexidine (in the form of Peridex® at a final concentration of 0.04% chlorhexidine) shows significant browning. Addition of a compound of Formula I to the chlorhexidine completely inhibits browning of the gelatin, as does inclusion of a compound of Formula I in the absence of chlorhexidine.
SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 53 The slight brown color formed by the action of glucose-6-phosphate on the gelatin surface alone and its prevention by a compound of Formula I demonstrates the utility of the present invention in preventing nonenzymatic browning of tooth surfaces. The enhanced browning in the presence of chlorhexidine and its prevention with a compound of Formula I demonstrates the utility of the present invention in preventing the anti-plaque agent-enhanced nonenzymatic browning which occurs with chlorhexidine.
EXAMPLE 14 As a demonstration of the general utility of compounds of the present invention to break undesired crosslinks in medically relevant biomolecules, Applicants conducted the following experiment with the amyloid peptide of Alzheimer’s disease. This 14 kDalton peptide comprises a main constituent of the large, plaque-like aggregates which form within the brain parenchyma of Alzheimer’s disease patients. The gradual accumulation of such amyloid plaques, together with other abnormal features such as perivascular amyloid and neurofibrillary tangles, is thought to account for certain of the neurotoxic and other pathogenic processes of this dementia, which is invariably fatal and presently incurable. The Alzheimer’s amyloid peptide is known to accumulate AGE modifications in vivo, and upon exposure to physiologically relevant concentrations of glucose, in vivo, which glycation enhances the formation of insoluble aggregates of the peptide, reminiscent of Alzheimer’s amyloid plaques.
AGE-B-peptide was prepared by incubating an aliquot of the soluble B-amyloid peptide, synthetically prepared and corresponding in sequence to the B-amyloid peptide found in the plaques typical of Alzheimer’s disease, in a neutral buffered glucose solution for three months, generally as described above for the preparation of AGE-BSA except that B-peptide was substituted for BSA as the glycation substrate.
The AGE-B-peptide, glycated and cross-linked after this prolonged exposure to glucose in vivo, was separated from low molecular weight reactants by size exclusion chromatography over a PFD-10 column), and iodinated by standard methods to give 1 25 1-AGE-B-peptide as the desired radiolabeled reagent useful to test or screen SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 54 compounds for molecular AGE-breaking activity according to the following procedure.
Aliquots of 1 25 I-AGE-B-peptide were incubated with or without added test compounds of the present invention, at predetermined concentrations 10mM Compound 766) for a predetermined tine overnight), after which a sample of the incubation mixture was prepared for denaturing gel electrophoresis (SDS-PAGE) and analyzed to determine apparent molecular weight according to well-known procedures.
Autoradiograms exposed on the resulting electrophoresis gels were scanned into a digital radiographic imaging and analysis system which was used to record radioactivity as a function of apparent molecular weight (electrophoretic mobility in SDS-containing buffer).
Inspection of the results of this experiment showed that if 1 25 1-AGE-B-peptide were not exposed to an «AGE-breaker» compound of the present invention, it eluted a high molecular weight (>40kDalton) band, suggesting that its glycation was accompanied by aggregation and the formation of stable covalent cross-links. If, however, 125I-AGE-Bpeptide was first incubated in a solution of an AGE crosslink-bearing agent of the present invention, the 1 25 1-AGE-B-peptide was significantly disaggregated as shown by the appearance of low molecular weight (>18 kDalton) iodinated material in the final radiogram. This experiment suggests not only that dinucleophilic thiazolium-like agents of the present invention can be used to hydrolyze covalent AGE-mediated crosslinks between protein strands, but also that such inhibition and reversal of AGEs can reverse the adverse molecular consequences of AGE accumulation on a protein relevant to human disease.
EXAMPLE The cross-link structure and related compounds of the present invention also find utility as antigens or haptens, to elicit antibodies specifically directed thereto. Such antibodies, likewise of the present invention, are useful in turn to identify AAA structures of the present invention. By constructing immunoassays employing anti-cross-link structure antibodies of the present invention, for instance, the degree to which proteins are modified by such cross-links can be measured. As discussed above, and depending on the half-life of the protein so modified, SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 immunochemical measurement of the cross-link epitopes on a protein sample, such as hemoglobin, provides an index of recent AGE-formation. Likewise, immunochemical detection of cross-link epitopes on circulating and/or tissue proteins can be used to monitor the course of therapy with agents of the present invention, which agents are directed toward inhibition of, and breaking of advanced glycation.
Cross-link-modified BSA for use as an immunogen can be prepared by coupling a cross-link structure with bovine serum albumin (BSA) using any of a number of wellknown divalent coupling reagents such as a carbodiimide like EDC. Various other haptens, antigens, and conjugated immunogens corresponding to the cross-link structures of the present invention, including without limitation those described specifically herein, can conveniently be prepared, either by isolation from incubation mixtures or by direct synthetic approaches. This cross-structure may then be used as an immunogen to raise a variety of antibodies which recognize specific epitopes or molecular features thereof.
In a preferred embodiment, the cross-link structure itself is considered a hapten, which is correspondingly coupled to any of several preferred carrier proteins, including for instance keyhole limpet hemocyanin (KLH), thyroglobulin, and most preferred, bovine serum albumin (BSA), using a divalent coupling reagents such as EDC, according to protocols widely circulated in the art.
The cross-link structure, whether alone or coupled to a carrier protein, may be employed in any well-recognized immunization protocol to generate antibodies and related immunological reagents that are useful in a number of applications owing to the specificity of the antibodies for molecular features of the cross-link structure.
Following a preferred protocol, any of several animal species may be immunized to produce polyclonal antisera directed against the cross-link structure-protein conjugate, including for instance mice, rats, hamsters, goats, rabbits, and chickens. The first of three of the aforesaid animal species are particularly desired choices for the subsequent production of hybridomas secreting hapten-specific monoclonal antibodies.
The production of said hybridomas from spleen cells of immunized animals may SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 56 conveniently be accomplished by any of several protocols popularly practiced in the art, and which describe conditions suitable for immortalization of immunized spleen cells by fusion with an appropriate cell line, e.g. a myeloma cell line. Said protocols for producing hybridomas also provide methods for selecting and cloning immune splenocyte/myeloma cell hybridomas and for identifying hybridomas clones that stably secrete antibodies directed against the desired epitope(s). Animal species such as rabbit and goat are more commonly employed for the generation of polyclonal antisera, but regardless of whether polyclonal antisera or monoclonal antibodies are desired ultimately, the hapten-modified carrier protein typically is initially administered in conjunction with an adjuvant such as Complete Freund’s Adjuvant. Immunizations may be administered by any of several routes,typically intraperitoneal, intramuscular or intradermal; certain routes are preferred in the art according to the species to be immunized and the type of antibody ultimately to be produced. Subsequently, booster immunizations are generally administered in conjunction with an adjuvant such as alum or Incomplete Freund’s Adjuvant. Booster immunizations are administered at intervals after the initial immunization; generally one month is a suitable interval, with blood samples taken between one and two weeks after each booster immunization.
Alternatively, a variety of so-called hyperimmunization schedules, which generally feature booster immunizations spaced closer together in time, are sometimes employed in an effort to produce anti-hapten antibodies preferentially over anti-carrier protein antibodies.
The antibody titers in post-boost blood samples can be compared for hapten-specific immune titer in any of several convenient formats including, for instance, Ouchterlony diffusion gels and direct ELISA protocols. In a typical direct ELISA, a defined antigen is immobilized onto the assay well surface, typically in a 96-well or microtiter plate format, followed by a series of incubations separated by rinses of the assay well surface to remove unbound binding partners. By way of nonlimiting example, the wells of an assay plate may receive a dilute, buffered aqueous solution of the hapten/carrier conjugate, preferably wherein the carrier protein differs from that used to immunize the antibody-producing animal to be tested; e.g. serum from AAA/KLH conjugate-immunized animal might be tested against assays wells decorated with immobilized AAA/BSA conjugate. Alternatively, the assay surface SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCT/US96/00663 57 may be decorated by incubation with the hapten alone. Generally, the surface of the assay wells is then exposed to a solution of an irrelevant protein, such as casein, to block unoccupied sites on the plastic surfaces. After rinsing with a neutral buffered solution that typically contains salts and a detergent to minimize non-specific interactions, the well is then contacted with one of a serial dilution of the serum prepared from the blood sample of interest (the primary antiserum). After rinsing again, the extent of test antibodies immobilized onto the assay wells by interaction with the desired hapten or hapten/carrier conjugate can be estimated by incubation with a commercially available enzyme-antibody conjugate, wherein the antibody portion of this secondary conjugate is directed against the species used to produce the primary antiserum; e.g. if the primary antiserum was raised in rabbits, a commercial preparation of anti-rabbit antibodies raised in goat and conjugated to one of several enzymes, such as horseradish peroxidase, can be used as the secondary antibody. Following procedures specified by the manufacturer, the amount of this secondary antibody can then be estimated quantitatively by the activity of the associated conjugate enzyme in a colorimetric assay. Many related ELISA or radioimmunometric protocols, such as competitive ELISAs or sandwich ELISAs, all of which are well know in the art, may optionally be substituted, to identify the desired antisera of high titer; that is, the particular antisera which give a true positive result at high dilution greater than 1/1000 and more preferably greater than 1/10,000).
Similar immunometric protocols can be used to estimate the titer of antibodies in culture supemrnatants from hybridomas prepared from spleen cells of immunized animals. In so characterizing antisera or hybridoma supernatants, it is desirable to employ a variety of control incubations, e.g. with different carrier proteins, related but structurally distinct haptens or antigens, and omitting various reagents in the immunometric procedure in order to minimize non-specific signals in the assay and to identify reliable determinations of antibody specificity and titer from false positive and false negative results. The types of control incubations to use in this regard are well known. Also, the same general immunometric protocols subsequently may be employed with the antisera identified by the above procedures to be of high titer and to be directed against specific structural determinants in the cross-link structures on biological samples, foodstuffs or other comestibles, or other amine-bearing substances SUBSTITUTE SHEET (RULE 26) WO 96/22095 PCTIUS96/00663 58 and biomolecules of interest. Such latter applications of the desired anti-aldehydemodified Amadori product antibodies, whether polyclonal or monoclonal, together with instructions and optionally with other useful reagents and diluents, including, without limitation, a set of molecular standards of the cross-link structure, may be provided in kit form for the convenience of the operator.
This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.
SUBSTITUTE SHEET (RULE 26)
Claims (45)
1. Use of one or more compounds selected from compounds of the formula: Y X R» 10 0 S S* 0 000 0 wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 0 II -CH 2 C-R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R is aryl, at least one of R 1 and R 2 is other than hydrogen and R 1 and R 2 are not part of an unsubstituted fused phenyl ring; a group of the formula -CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula O R» -CH2C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) and are both lower alkyl groups; and X is a pharmaceutically acceptable anion; in the manufacture of a pharmaceutical composition for, in a human or non- human animal, improving the elasticity or reducing wrinkles of the skin, treating (ii) diabetes or treating or preventing (iii) adverse sequelae of diabetes, (iv) kidney damage, damage to blood vasculature, (vi) hypertension, (vii) retinopathy, (viii) damage to lens proteins, (ix) cataracts, peripheral neuropathy or (xi) osteoarthritis.
2. Use of one or more compounds selected from compounds of the formula: Y X R N S wherein RI and R2 are independently selected from the group consisting of S hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 00′ 0 II -CH 2 C-R S: wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R S is aryl, at least one of R 1 and R 2 is other than hydrogen and R 1 and R 2 are not part of *0 an unsubstituted fused phenyl ring; a group of the formula -CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; 61 or a group of the formula O R» II 1 -CH 2 C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) R» and are both lower alkyl groups; and X is a pharmaceutically acceptable anion; in the manufacture of a composition for, in a human or non-human animal, inhibiting or reversing the discoloration of teeth resulting from non-enzymatic browning in the oral cavity. 5
3. Use of one or more compounds selected from compounds of the formula: Y X° 0@ I Z S wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 0 0 00 0 II -CH 2 C-R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R ,saryl, at least one of R 1 and R 2 is other than hydrogen and R 1 and R 2 are not part of an ubstituted fused phenyl ring; a group of the formula -CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula OR» II I -CH 2 C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) R» and are both lower alkyl groups; and X is a pharmaceutically acceptable anion; in the manufacture of a composition for the treatment of a disease selected from the group consisting of retinopathy, cataracts, diabetic kidney disease, glomerulosclerosis, peripheral vascular disease, arteriosclerosis obliterans, peripheral neuropathy, stroke, hypertension, atherosclerosis, osteoarthritis, periarticular rigidity, the stiffening of joints, glomerulonephritis, structural lesions caused by the S: formation of advanced glycosylation endproducts, diabetes induced changes in the deformability of red blood cells, and decreased bone formation.
4. Use according to any one of Claims 1 to 3, wherein Y is a 2-(substituted or unsubstituted)-phenyl-2-oxoethyl group. *0•
5. Use according to Claim 4, wherein said compound is: 3-(2-phenyl-2-oxoethyl)-4-methylthiazolium bromide or another biologically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)thiazolium bromide or another biologically acceptable salt thereof; 3 2 3 ‘,5′-di-tert-butyl-4’-hyroxyphenyl)-2-oxoethyl]-5-methyl-thiazolium bromide or another biologically acceptable salt thereof; 3 2 3 ‘,5′-tert-butyl-4′-hyroxyphenyl)-2-oxoethyl]-4-methyl-5-vinyl 4i4azolium bromide or another biologically acceptable salt thereof; 63 3-(2-phenyl-2-oxoethyl)-4,5-dimethyl-thiazolium bromide or another biologically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)-4-methyl-5-vinyl-thiazolium bromide or another biologically acceptable salt thereof; or 3-[2-(4′-diethylaminophenyl)-2-oxoethyl]-thiazolium bromide or another biologically acceptable salt thereof.
6. Use according to any one of Claims 1 to 3, wherein Y is a 2-amino-2-oxoethyl group.
7. Use according to Claim 6, wherein said compound is: 3-(2-amino-2-oxoethyl)-benzothiazolium bromide or another biologically acceptable salt thereof; or 3-(2-amino-2-oxoethyl)-4-methyl-5-(2-hydroxyethyl)-thiazolium bromide or S another biologically acceptable salt thereof. S
8. Use according to any one of Claims 1 to 3, wherein said compound is: 2,3-diamino-thiazolium mesitylenesulfonate or another biologically acceptable goC S salt thereof; 20 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride or another biologically acceptable salt thereof; 3-amino-5-(2-hydroxyethyl)-4-methyl-thiazolium mesitylenesulfonate or another biologically acceptable salt thereof; or 0 3-(2-methyl-2-oxoethyl)thiazolium chloride or another biologically acceptable 2 salt thereof.
9. Use according to Claim 1, wherein said composition is for treating (ii) diabetes @o or treating or preventing (iii) adverse sequelae of diabetes. o0
10. Use according to Claim 1, wherein said composition is for treating or venting (iv) kidney damage. 64
11. Use according to Claim 1, wherein said composition is for treating or preventing damage to blood vasculature.
12. Use according to Claim 1, wherein said composition is for treating or preventing (vi) hypertension.
13. Use according to Claim 1, wherein said composition is for treating or preventing (vii) retinopathy.
14. Use according to Claim 1, wherein said composition is for treating or preventing (viii) damage to lens proteins.
Use according to Claim 1, wherein said composition is for treating or preventing (ix) cataracts.
16. Use according to Claim 1, wherein said composition is for treating or preventing peripheral neuropathy.
17. Use according to Claim 1, wherein said composition is for treating or preventing (xi) osteoarthritis.
18. A method for treating a foodstuff containing protein material so as to inhibit the undesired molecular changes therein caused by the formation of advanced glycosylation endproducts of a target protein within said foodstuff, said method .*25 comprising treating the foodstuff with an effective amount of a dinucleophilic S. thiazolium compound of the formula: Y X0 R S wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 0 i -CH 2 C-R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R is aryl, at least one of R 1 and R 2 is other than hydrogen and R 1 and R 2 are not part of an unsubstituted fused phenyl ring; a group of the formula -CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula O R» i -CH 2 C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) R» and are both lower alkyl groups; and X is a pharmaceutically acceptable anion; 0* said dinucleophilic thiazolium compound being capable of reacting with a o sugar-derived, non-enzymatically formed cross-link structure, found both in vitro and in vivo, which includes an a-dicarbonyl moiety.
19. The method of Claim 18, wherein said a-dicarbonyl moiety of the crosslink structure is a diketone (dione) structure.
I 66 The method of Claim 18 or Claim 19, wherein said a-dicarbonyl moiety of the crosslink structure is a diketone (dione) structure according to the formula: 0 4 f O0 where A and B are each independently sites of attachment to the nucleophilic atom of a biomolecule.
21. The method of Claim 20, wherein each site of attachment to the nucleophilic atom of a biomolecule is an amino group of a biomolecule.
22. The method of Claim 20 or Claim 21, wherein said biomolecule is a protein.
23. The method of any one of Claims 18 to 22, wherein said crosslink structure forms an intermolecular or an intramolecular crosslink.
24. The method of any one of Claims 18 to 23, wherein Y is a 2-(substituted or unsubstituted)-phenyl-2-oxoethyl group.
The method of Claim 24, wherein said compound is: 3 -(2-phenyl-2-oxoethyl)-4-methylthiazolium bromide or another biologically S acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)thiazolium bromide or another biologically acceptable salt thereof; 3 2 3 ‘,5′-di-tert-butyl-4’-hyroxyphenyl)-2-oxoethyl]-5-methyl-thiazolium bromide or another biologically acceptable salt thereof; 3 2 3 ‘,5′-tert-butyl-4’-hyroxyphenyl)-2-oxoethyl]-4-methyl-5-vinyl thiazolium bromide or another biologically acceptable salt thereof; 3 -(2-phenyl-2-oxoethyl)-4,5-dimethyl-thiazolium bromide or another L iologically acceptable salt thereof; *se 3 2 -phenyl- 2 -oxoethyl)-4-methyl-5-vinyl-thiazolium bromide or another biologically acceptable salt thereof; or 3 2 4 ‘-diethylaminophenyl)-2-oxoethyl]-thiazolium bromide or another biologically acceptable salt thereof.
26. The method of any one of Claims 18 to 23, wherein Y is a 2 -amino-2-oxoethyl group.
27. The methodof Claim 26, wherein said compound is: 3 2 -amino-2-oxoethyl)-benzothiazolium bromide or another biologically acceptable salt thereof; or 3 2 -amino- 2 -oxoethyl)-4-methyl-5-(2-hydroxyethyl)-thiazolium bromide or another biologically acceptable salt thereof.
28. The method of any one of Claims 18 to 23, wherein said compound is: 2,3-diamino-thiazolium mesitylenesulfonate or another biologically acceptable salt thereof; 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride or another biologically acceptable salt thereof; 3 -amino-5-(2-hydroxyethyl)-4-methyl-thiazolium mesitylenesulfonate or another biologically acceptable salt thereof; or 3 2 -methyl-2-oxoethyl)thiazolium chloride or another biologically acceptable salt thereof. .*25
29. A compound of the structural formula: *R Y R S wherein: S(i) Y and Z are both amino groups and R 1 and R 2 are independently 68 selected from the group consisting of hydroxy(lower)alkyl, lower acyloxy(lower)alkyl and lower alkyl, or one of R 1 or R 2 is hydrogen, or R 1 or R 2 together with their ring carbons form an aromatic fused ring substituted by one or more amino, halo or alkylenedioxy groups; or (ii) R 1 R 2 and Z are hydrogen; and Y is a group of the formula -CH 2 C(=O)R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, with the proviso that Y is not 2-phenyl-2-oxoethyl or 2 3 ‘-methoxyphenyl)-2-oxoethyl; a group of the formula -CH2R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or alkoxycarbonyl groups; or R» and are both lower alkyl groups; or (iii) R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; and Y is an alkynylmethyl group or a group of the formula 5 -CH 2 C(=O)NHR wherein R is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or alkoxycarbonyl groups; or S(iv) R 1 and R 2 are independently selected from the group consisting of :0 hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, with the provisos that RI and R 2 cannot both be ij hydrogen and R 1 and R 2 cannot both be methyl, and with the further V proviso that, when R 2 is hydrogen, R 1 is other than methyl; or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen; and Y is amino; or R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl; or R 1 and R 2 together with their ring carbons form an armatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is an amino group; and Y is a group of the formula -CH 2 C(=O)R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups; or a group of the formula -CH 2 R’ wherein R’ is hydrogen or a lower alkyl or aryl group; and X is a pharmaceutically acceptable anion.
30. The compound of Claim 29 wherein Y is a 2-(substituted or unsubstituted) phenyl-2-oxoethyl group or a 2-amino-2-oxoethyl group.
31. A compound which is: 3 2 3 ‘,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-5-methyl-thiazolium .*25 bromide or another biologically acceptable salt thereof; 3 2 -(3′,5′-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl)]-4-methyl-5-vinyl- thiazolium bromide or another biologically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)-4-methyl-5-vinyl-thiazolium bromide or another biologically acceptable salt thereof; *0 3-[2-(4′-diethylaminophenyl)-2-oxoethyl]-thiazolium bromide or another «t gically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide or another biologically acceptable salt thereof; 3-(2-amino-2-oxoethyl)-4-methyl-5-(2-hydroxyethyl)thiazolium bromide or another biologically acceptable salt thereof; 3-amino-5-(2-hydroxyethyl)-4-methylthiazolium mesitylenesulfonate or another biologically acceptable salt thereof; or 3-(2-methyl-2-oxoethyl)thiazolium chloride or another biologically acceptable salt thereof.
32. Use of a compound of any one of Claims 29 to 31 for, in a human or non- human animal, improving the elasticity or reducing wrinkles of the skin, treating (ii) diabetes or treating or preventing (iii) adverse sequelae of diabetes, (iv) kidney damage, damage to blood vasculature, (vi) hypertension, (vii) retinopathy, (viii) damage to lens proteins, (ix) cataracts, peripheral neuropathy or (xi) osteoarthritis.
33. Use of a compound of any one of Claims 29 to 31 for, in a human or non- human animal, inhibiting or reversing the discoloration of teeth resulting from non- enzymatic browning in the oral cavity. 9**9 9 9* 00 0* 0 00 0r 0000
34. Use of a compound of any one of Claims 29 to 31 for the treatment of a disease selected from the group consisting of retinopathy, cataracts, diabetic kidney disease, glomerulosclerosis, peripheral vascular disease, arteriosclerosis obliterans, peripheral neuropathy, stroke, hypertension, atherosclerosis, osteoarthritis, periarticular rigidity, the stiffening of joints, glomerulonephritis, structural lesions caused by the formation of advanced glycosylation endproducts, diabetes induced changes in the deformability of red blood cells, and decreased bone formation.
A method for, in a human or non-human animal, improving the elasticity or reducing wrinkles of the skin, treating (ii) diabetes or treating or preventing (iii) t erse sequelae of diabetes, (iv) kidney damage, damage to blood vasculature, (vi) hypertension, (vii) retinopathy, (viii) damage to lens proteins, (ix) cataracts, (x) peripheral neuropathy or (xi) osteoarthritis, comprising administration of an effective amount of a pharmaceutical composition comprising one or more compounds selected from compounds of the formula: Y X R N R S wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 andR 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 0 II -CH 2 C-R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R is aryl, at least one of R 1 and R 2 is other than hydrogen and R 1 and R 2 are not part of an unsubstituted fused phenyl ring; a group of the formula -CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula O R» II I -CH 2 C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group *to can be substituted by an aryl group, or an aryl group, which aryl group can be .00: substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) R» and are both lower alkyl groups; and X is a pharmaceutically acceptable anion; 0d d a carrier therefor.
36. A method for, in a human or non-human animal, inhibiting or reversing the discoloration of teeth resulting from non-enzymatic browning in the oral cavity, comprising administration of an effective amount of a composition comprising one or more compounds selected from compounds of the formula: Y X RI R S wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula 0 11 -CH 2 C-R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R is aryl, at least one of R 1 and R 2 is other than hydrogen and R1 and R 2 are not part of an unsubstituted fused phenyl ring; a group of the formula -CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula O R» *II e. -CH2C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be to: substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) 000 R» and are both lower alkyl groups; r7nd X is a pharmaceutically acceptable anion; S a carrier therefor. a*! 0f a^^FtC^
37. A method for the treatment of a disease selected from the group consisting of retinopathy, cataracts, diabetic kidney disease, glomerulosclerosis, peripheral vascular disease, arteriosclerosis obliterans, peripheral neuropathy, stroke, hypertension, atherosclerosis, osteoarthritis, periarticular rigidity, the stiffening of joints, glomerulonephritis, structural lesions caused by the formation of advanced glycosylation endproducts, diabetes induced changes in the deformability of red blood cells, and decreased bone formation, comprising administration of an effective amount of a pharmaceutical composition comprising one or more compounds selected from compounds of the formula: Y X R N 0 R S wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, lower acyloxy(lower)alkyl, lower alkyl and lower alkenyl, or R 1 and R 2 together with their ring carbons form an aromatic fused ring which can be substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula L3 45 -CH 2 C-R wherein R is a lower alkyl, lower alkoxy, hydroxy, amino or aryl group, which aryl group can be substituted by one or more lower alkyl, lower alkoxy, halo, di(lower alkyl)amino, hydroxy, nitro or alkylenedioxy groups, and wherein, when R is aryl, at least one of R’ and R 2 is other than hydrogen and R 1 and R 2 are not part of an unsubstituted fused phenyl ring; a group of the formula CH 2 R’ wherein R’ is hydrogen, or a lower alkyl, lower alkynyl or aryl group; or a group of the formula O0 R» K B II 1 -CH 2 C-N-R»‘ wherein R» is hydrogen and is a lower alkyl group, which lower alkyl group can be substituted by an aryl group, or an aryl group, which aryl group can be substituted by one or more lower alkyl, halo or lower alkoxycarbonyl groups; or (ii) R» and are both lower alkyl groups; and X is a pharmaceutically acceptable anion; and a carrier therefor.
38. The method of any one of Claims 35 to 37, wherein Y is a 2-phenyl-2-oxoethyl group.
39. The method of Claim 38, wherein said compound is: 3-(2-phenyl-2-oxoethyl)-4-methylthiazolium bromide or another biologically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)thiazolium bromide or another biologically acceptable salt thereof; 3-[2-(3′,5′-di-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-5-methyl-thiazolium bromide or another biologically acceptable salt thereof; 3-[2-(3′,5′-tert-butyl-4′-hydroxyphenyl)-2-oxoethyl]-4-methyl-5-vinyl- thiazolium bromide or another biologically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)-4,5-dimethyl-thiazolium bromide or another biologically acceptable salt thereof; 3-(2-phenyl-2-oxoethyl)-4-methyl-5-vinyl-thiazolium bromide or another biologically acceptable salt thereof; or 3-[2-(4’-diethylaminophenyl)-2-oxoethyl]-thiazolium bromide or another biologically acceptable salt thereof.
40. The method of any one of Claims 35 to 37, wherein Y is a 2-amino-2-oxoethyl group. A0
41. The method of Claim 40, wherein said compound is: 3-(2-amino-2-oxoethyl)-benzothiazolium bromide or another biologically a ptable salt thereof; or 3 2 -amino- 2 -oxoethyl)-4-methyl-5-(2-hydroxyethyl)-thiazolium bromide or another biologically acceptable salt thereof.
42. The method of any one of Claims 35 to 37, wherein said compound is: 2,3-diamino-thiazolium mesitylenesulfonate or another biologically acceptable salt thereof; 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride or another biologically acceptable salt thereof; 3-amino-5-(2-hydroxyethyl)-4-methyl-thiazolium mesitylenesulfonate or another biologically acceptable salt thereof; or 3-(2-methyl-2-oxoethyl)thiazolium chloride or another biologically acceptable salt thereof.
43. Use according to any one of Claims 1 to 17 and 32 to 34, substantially as described herein and with reference to any one of Examples 1 to
44. A method according to any one of Claims 18 to 28 and 35 to 42, substantially as described herein and with reference to any one of Examples 1 to
45. A compound according to any one of Claims 29 to 31, substantially as described herein and with reference to any one of Examples 1 to DATED this 14 th day of October, 1999. 25 ALTEON INC and THE PICOWER INSTITUTE FOR MEDICAL RESEARCH By their Patent Attorneys S MADDERNS *o OFF\
AU47599/96A
1995-01-18
1996-01-18
Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation Endproducts
Ceased
AU714607C
(en)
Applications Claiming Priority (7)
Application Number
Priority Date
Filing Date
Title
US08/375155
1995-01-18
US08/375,155
US5656261A
(en)
1995-01-18
1995-01-18
Preventing and reversing advanced glycosylation endproducts
US47318495A
1995-06-07
1995-06-07
US08/473184
1995-06-07
US08/588,249
US5853703A
(en)
1995-01-18
1996-01-18
Preventing and reversing the formation of advanced glycosylation endproducts
PCT/US1996/000663
WO1996022095A2
(en)
1995-01-18
1996-01-18
Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
US08/588249
1996-01-18
Publications (3)
Publication Number
Publication Date
AU4759996A
AU4759996A
(en)
1996-08-07
AU714607B2
true
AU714607B2
(en)
2000-01-06
AU714607C
AU714607C
(en)
2000-12-14
Family
ID=
Citations (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
EP0369453A2
(en)
*
1988-11-18
1990-05-23
Takeda Chemical Industries, Ltd.
AGE-formation inhibitory agents
US5262152A
(en)
*
1984-03-19
1993-11-16
The Rockefeller University
Amidrazones and derivatives thereof
EP0586806A1
(en)
*
1992-07-13
1994-03-16
Hoechst Aktiengesellschaft
Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives for the treatment of diseases which are mediated by non-enzymatical glycosylation
Patent Citations (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5262152A
(en)
*
1984-03-19
1993-11-16
The Rockefeller University
Amidrazones and derivatives thereof
EP0369453A2
(en)
*
1988-11-18
1990-05-23
Takeda Chemical Industries, Ltd.
AGE-formation inhibitory agents
EP0586806A1
(en)
*
1992-07-13
1994-03-16
Hoechst Aktiengesellschaft
Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives for the treatment of diseases which are mediated by non-enzymatical glycosylation
Also Published As
Publication number
Publication date
US7022719B2
(en)
2006-04-04
US20040034074A1
(en)
2004-02-19
US20020192842A1
(en)
2002-12-19
US6440749B1
(en)
2002-08-27
US20070025926A1
(en)
2007-02-01
US6007865A
(en)
1999-12-28
AU4759996A
(en)
1996-08-07
NO973308L
(en)
1997-09-18
FI119756B
(en)
2009-03-13
US20080132553A1
(en)
2008-06-05
FI973031A0
(en)
1997-07-17
NO315930B1
(en)
2003-11-17
FI973031A
(en)
1997-09-15
NO973308D0
(en)
1997-07-17
Similar Documents
Publication
Publication Date
Title
US5853703A
(en)
1998-12-29
Preventing and reversing the formation of advanced glycosylation endproducts
US6007865A
(en)
1999-12-28
Reversing the formation of advanced glycosylation endproducts
USRE38330E1
(en)
2003-11-25
Preventing and reversing advanced glycosylation endproducts
US5130324A
(en)
1992-07-14
2-alkylidene-aminoguanidines and methods of use therefor
US5130337A
(en)
1992-07-14
Amidrazones and derivatives thereof
US5272165A
(en)
1993-12-21
2-alkylidene-aminoguanidines and methods of use therefor
US5100919A
(en)
1992-03-31
Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5358960A
(en)
1994-10-25
Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles
US5258381A
(en)
1993-11-02
2-substituted-2-imidazolines
US5262152A
(en)
1993-11-16
Amidrazones and derivatives thereof
US5318982A
(en)
1994-06-07
Inhibition of the advanced glycosylation of proteins using substituted-1,2,4-triazoles
US5661139A
(en)
1997-08-26
Bis-(2-aryl) hydrazones
US5698563A
(en)
1997-12-16
Bis- hydrazones!
AU714607C
(en)
2000-12-14
Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation Endproducts
US5243071A
(en)
1993-09-07
2-alkylidene-aminoguanidines and methods of use therefor
US5612332A
(en)
1997-03-18
Di- and triaminoguanidines, and methods of use
US20090088461A1
(en)
2009-04-02
Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet
US5326779A
(en)
1994-07-05
Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles
US5254593A
(en)
1993-10-19
Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
AU724319B2
(en)
2000-09-14
Substituted imidazolium salts and their use for the inhibition of protein ageing
WO2009023207A1
(en)
2009-02-19
Thiazolium compounds for treating gastrointestinal complications
US5877217A
(en)
1999-03-02
N-acylaminoalkyl-hydrazinecarboximidamides
US20040198795A1
(en)
2004-10-07
Substituted imidazoliums and methods of use therefor
Legal Events
Date
Code
Title
Description
2000-05-04
FGA
Letters patent sealed or granted (standard patent)
2000-05-18
DA2
Applications for amendment section 104
Free format text:
THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20000404
2000-12-14
DA3
Amendments made section 104
Free format text:
THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20000518
